Conjugate of nucleic acid or derivative thereof and cell, preparation method and application thereof

By using the sorting enzyme mgSrtA to conjugate nucleic acids or their derivatives to the cell surface, the problem of nucleic acids not being considered as substrates has been solved, enabling the efficient application of nucleic acids in cell internalization and drug delivery.

CN118974251APending Publication Date: 2024-11-15WESTLAKE UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202280094330.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2022-01-28
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

In the prior art, nucleic acids are not considered as substrates for sorting enzymes and cannot be stably anchored to the cell surface by sorting enzyme catalysis, which limits the application of nucleic acids in biological conjugation and delivery.

Method used

By using sorting enzymes such as mgSrtA, nucleic acids or their derivatives are brought into contact with cells, causing them to be conjugated to the cell surface by the sorting enzyme catalysis. In particular, stable anchoring of nucleic acids is achieved by recognizing and attaching to amino sugars on the cell membrane, such as glycosaminoglycans.

Benefits of technology

This technology enables stable binding of nucleic acids or their derivatives to cells, providing new methods for cell labeling and nucleic acid drug delivery, and enhancing the efficiency of nucleic acid internalization and downstream biological processes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005063429570000241
    Figure BDA0005063429570000241
  • Figure BDA0005063429570000251
    Figure BDA0005063429570000251
  • Figure HDA0005063429710000011
    Figure HDA0005063429710000011
Patent Text Reader

Abstract

The present invention provides conjugates of a nucleic acid or a derivative thereof and a sortase. The invention also provides conjugates of nucleic acids or derivatives thereof with cells, as well as methods of preparing such conjugates promoted by sortase. The present disclosure further provides methods of delivering nucleic acids or derivatives thereof to cells promoted by sortase.
Need to check novelty before this filing date? Find Prior Art

Description

Sequence Listing

[0001] This application contains a Sequence Listing, which is submitted electronically in ASCII format and is incorporated herein by reference in its entirety. Technical Field

[0002] The present invention relates to novel reactions of nucleic acids catalyzed by sortase, as well as products of such reactions, and uses of such reactions and such products. Background of the Invention

[0003] Sortases (Srts), such as sortase A (SrtA) and sortase B (SrtB), are a group of transpeptidases that mediate the attachment of peptides to the bacterial cell wall and the assembly of pili. 1 In Staphylococcus aureus (S. aureus), peptides with the LPXTG motif were reported to be recognized by SrtA and covalently anchored to the NH2-GGG peptide on the cell wall via a transpeptidation reaction, in which the LPXTG motif serves as a sorting signal (first substrate) and NH2-GGG serves as a nucleophile. 2 (Second substrate).

[0004] So far, the natural substrates that can be recognized by sortases as sorting signals are amino acid motifs, although the sequences of the amino acid motifs differ between different sortase classes. 1,2 As for nucleophiles, the N-terminal pentaglycine is known to be a typical substrate for SrtA. However, other nucleophiles, including amino sugars 3 (e.g., puromycin) and internal lysine side chains, which can also act as nucleophiles via isopeptide bonds 4 Molecules with unbranched primary amines can also act as nucleophiles to attach to LPXTG-containing moieties 5 .

[0005] To expand the application of Srt-mediated bioconjugation, multiple enzyme variants of Srt with different characteristics have been developed. Liu et al. used yeast display to evolve a sortase variant (eSrtA, 5M) with 140-fold increased recognition activity for LPETG-containing peptides. 6 Another variant, Srt7M, was later shown to mediate bioconjugation between the LPXTG substrate and various amines. 5 Chen and colleagues developed a FRET-based platform for directed evolution and found another variant based on the 5M variant (Chen 2016) that significantly improved the kinetics of the conjugation reaction. 7 Chen and colleagues subsequently evolved a “promiscuous” SrtA variant, mgSrtA, which is able to attach LPXTG-containing peptides to the N-terminal single glycine instead of an oligoglycine chain. 8Recently, a SrtA variant that recognizes LMVGG was developed, which enables sortation tagging (sortase-mediated transpeptidation reaction) of endogenous amyloid β (Aβ) protein, an Alzheimer's disease (AD)-associated protein. 9 As a result of these efforts, sorting tags now enable efficient bioconjugation of proteins. SUMMARY OF THE INVENTION

[0006] The present inventors surprisingly found that nucleic acids (e.g. DNA and RNA) or nucleic acid derivatives (e.g. PNA (peptide nucleic acid)) can serve as substrates for sortases. For example, the present inventors surprisingly found that in the presence of a sortase such as mgSrtA, nucleic acids or nucleic acid derivatives (e.g. DNA oligomers, RNA oligomers or PNA) can be stably anchored to the surface of a cell. This is unexpected and surprising because sortases are thought to be transpeptidases that attach peptides with motifs such as LPXTG to the N-terminal oligoglycine residues of proteins. Nucleic acids (e.g. DNA or RNA oligonucleotides) have not been reported as substrates for sortases before. Such reactions of nucleic acids or their derivatives promoted by sortases were previously unknown.

[0007] In one embodiment, the present disclosure provides a conjugate of a nucleic acid or a derivative thereof and a sortase.

[0008] In one embodiment, the present disclosure provides a conjugate of a cell and a nucleic acid or a derivative thereof.

[0009] In one embodiment, the disclosure provides a nucleic acid comprising an anchoring region, preferably enriched in guanine, suitable for attachment to a cell. In one embodiment, the disclosure provides a nucleic acid comprising an anchoring region, a region for PCR amplification, a programmable region (e.g., a barcode region) to distinguish individual cells, and a capture sequence for sequence enrichment. For example, the anchoring region can be enriched in guanine. For another example, the region for PCR amplification is guanine-deficient. For another example, the capture sequence can be a poly-A (adenine) sequence or a capture sequence suitable for high-throughput sequencing.

[0010] In one embodiment, the present disclosure provides a method for preparing a conjugate of a cell and a nucleic acid or a derivative thereof, comprising contacting a nucleic acid or a derivative thereof, a cell, and a sortase, wherein the nucleic acid or a derivative thereof is conjugated to the cell, and wherein the conjugation of the nucleotide or derivative thereof to the cell is catalyzed by the sortase.

[0011] In one embodiment, the present disclosure provides a method for delivering a nucleic acid or a derivative thereof to a cell, comprising providing a nucleic acid or a derivative thereof and a sortase to the vicinity of the cell, wherein the nucleic acid or a derivative thereof is conjugated to the cell by catalysis of the sortase, and wherein the nucleic acid or a derivative thereof is internalized into the cell.

[0012] In one embodiment, the present disclosure provides a method for identifying a cell, comprising contacting a nucleic acid or a derivative thereof, a cell, and a sorting enzyme, wherein the nucleic acid or a derivative thereof is conjugated to the cell, wherein the conjugation of the nucleic acid or a derivative thereof to the cell is catalyzed by the sorting enzyme, and wherein the nucleotide or derivative thereof comprises an anchor region, a region for PCR amplification, a barcode region, and a capture sequence for sequence enrichment.

[0013] In one embodiment, the disclosure provides a kit comprising a sortase described herein and a nucleic acid or derivative thereof. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] Figure 1 shows a schematic diagram of a method for enhancing the efficacy of oligonucleotide drugs by local injection into targeted cells using sortase. The upper figure (Figure 1A) shows the diffusion of oligonucleotides after local injection without sortase. The lower figure (Figure 1B) shows that after local injection of sortase, the oligonucleotide is conjugated to the cell membrane by sortase promotion, resulting in the subsequent internalization of the oligonucleotide into the cell.

[0015] Figure 2 shows a schematic diagram of an example of a local injection site for a nucleic acid drug. The nucleic acid drug or its bioconjugate can be injected locally with a sortase into (A) a tumor site; (B) an epidural site; (C) an intravitreal site; or (D) an intracerebral site.

[0016] Figure 3 A schematic diagram of a nucleic acid drug delivered to a cell as described herein and sensed by a receptor in the cell is shown. The receptor may include a Toll-like receptor (TLR) on the membrane of an endosome, a cGAS protein in the cytoplasm, and a RIG-I protein in the cytoplasm. The figure shows examples of interactions between heterodimers of TLR7 / TLR8 receptors and single-stranded RNA (ssRNA), between TLR9 dimers and unmethylated CpG, and between TLR3 dimers and double-stranded RNA (dsRNA) in endosomes. Figure 3 Examples of interactions between cGAS dimers and dsDNA, and between RIG-1 and double-stranded RNA (dsRNA) in the cytoplasm are also shown.

[0017] Figure 4 shows a schematic diagram of an example of a downstream mechanism of action of a nucleic acid drug delivered to a cell as described herein. Figures 4A, 4B and 4C show that a nucleic acid drug can hybridize with a targeted mRNA, resulting in degradation of the mRNA. Figures 4D and 4E show that a nucleic acid drug can be used as a spatial blocking oligonucleotide to regulate the expression of a targeted mRNA without degrading the mRNA. Figure 4F shows that a nucleic acid drug can also target circular RNA by sequence hybridization and result in degradation of circular RNA. "RISC" means "RNA-induced silencing complex", "ASO" means "antisense oligonucleotide", and "mRNA" means "messenger RNA".

[0018] Figure 5 Schematic diagrams of protein, peptide or antigen products produced by nucleic acid drugs delivered to cells as described herein are shown. After internalization of the nucleic acid drug, the nucleic acid is translated in the cytoplasm and its products can reach a variety of intracellular or extracellular destinations to exert downstream functions. Examples of destinations include (1) the nucleus; (2) the cytoplasm; (3) the cell membrane; and (4) presentation to extracellular sites via the MHC complex.

[0019] Fig. 6A The fluorescence signals of FITC (fluorescein isothiocyanate), biotin (biotin was subsequently detected by streptavidin-phycoerythrin (SAv-PE)) and TAMRA-modified oligomers attached to K562 cells in the presence of mgSrtA are shown. The fluorescence signals of FITC, PE (biotin) and TAMRA were collected by flow cytometry and plotted between five samples, including negative control (NC), 4-nt polyadenosine (4-nt poly-A) modified by FITC, biotin and TAMRA, respectively, 4-nt polythymine (4-nt poly-T) modified by FITC, biotin and TAMRA, respectively, 4-nt polycytosine (4-nt poly-C) modified by FITC, biotin and TAMRA, respectively, and 4-nt polyguanine (4-nt poly-G) modified by FITC, biotin and TAMRA, respectively.

[0020] Figure 6BFITC signals collected from FITC-modified oligonucleotides attached to K562 cells are shown and plotted between six samples, including negative control (NC), FITC-modified 32-nt poly A (32-nt poly A), FITC-modified 32-nt poly T (32-nt poly T), FITC-modified 32-nt poly C (32-nt poly C), FITC-modified 4-nt poly G (32-nt poly G), and FITC-modified 34-nt mixed nucleotides (34-nt mixture). The sequence of the 34-nt mixture is shown in SEQ ID NO: 1: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCT. The amino acid sequence of mgSrtA is shown in SEQ ID NO: 2: KPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLNRGVSFAEENESLDDQNISIAGHTFIGRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVGVLDEQKGKDKQLTLITCDDLNRETGVWETRKILVATEVK. Unless otherwise indicated, mgSrtA used in this application is SEQ ID NO: 2.

[0021] Fig. 7 shows the percentage of cells of oligonucleotide positive labeling modified by FITC, TAMRA and biotin and the figure of the mean fluorescence intensity of labeled cells.The amount of biotin is represented by SAv-PE.In the presence of (mgSrtA+) or no (mgSrkA-)mgSrtA, cells are labeled with 4-nt or 32-nt poly-A, poly-T, poly-C or poly-G modified with FITC, TAMRA and biotin, respectively.The 34nt oligomer (34 mixtures) modified by FITC with mixed A, T, C and G nucleotides are included to compare the labeling efficiency of the oligonucleotide (SEQ ID NO:1).For each 4-nt oligomer, three different modifications (FITC, TAMRA and biotin) are included to confirm the mgSrtA dependent labeling of cells.

[0022] Fig. 7A The fluorescence signals of FITC for cells labeled with 4-nt poly-A, poly-T, poly-C or poly-G modified with FITC in the presence or absence of mgSrtA are shown, expressed as the mean fluorescence intensity and the percentage of positively labeled cells, respectively.

[0023] Figure 7BFluorescence signals of TAMRA for cells labeled with 4-nt poly-A, poly-T, poly-C, or poly-G modified with TAMRA in the presence or absence of mgSrtA, respectively, are shown, expressed as mean fluorescence intensity and percentage of positively labeled cells, respectively.

[0024] Figure 7C Fluorescence signals of anti-biotin antibodies for cells labeled with biotin-modified 4-nt poly-A, poly-T, poly-C, or poly-G, respectively, in the presence or absence of mgSrtA are shown, expressed as mean fluorescence intensity and percentage of positively labeled cells, respectively.

[0025] Fig.7D The fluorescence signals of FITC for cells labeled with 32-nt poly-A, poly-T, poly-C or poly-G, respectively, in the presence or absence of mgSrtA are shown, expressed as the mean fluorescence intensity and the percentage of positively labeled cells, respectively. A FITC-modified 34-nt oligomer (34Mix) with mixed A, T, C and G nucleotides was included to compare the labeling efficiency of the oligomers.

[0026] Figure 8 Schematic diagram of screening for preferred oligonucleotides for cell labeling promoted by mgSrtA. For example, a 79-nt oligonucleotide was designed, which included a PCR handle, a 12-nt random nucleotide, and a poly A tail. The oligonucleotide was incubated with cells in the presence of mgSrtA. The cells labeled with the oligonucleotide were then subjected to a SMART-seq experiment. The oligonucleotide was amplified in two consecutive PCRs. The first PCR enriched the oligonucleotides from endogenous RNA. And the second PCR added P5 and P7 adapter sequences for high-throughput sequencing on the Illumina platform. The screening experiment used an oligonucleotide library (mixed sequence) to label cells, rather than a single oligo with a fixed sequence. The 12-nt random sequence can be called a 12-nt barcode, which consists of 4 12 At the end of the screening, the oligomers that labeled the most cells were reflected by the highest abundance in the high-throughput sequencing data.

[0027] Fig. 9 Shown in Figure 8 Motifs identified by high throughput sequencing after the screening experiment shown in . The upper figure shows that guanine nucleotides are significantly enriched from the screening experiment in the presence of mgSrtA (mgSrtA+). The lower figure shows the motif analysis in the absence of mgSrtA (mgSrtA-) as a control. Fig. 9The upper and lower figures show the distribution of nucleotides across the 12-nt barcode region. The x-axis represents the sequence position on the 12-nt barcode region, and the y-axis is occupied by the four different nucleotides in proportion. Larger letters (e.g., "G" at position 1) mean that the nucleotide has a higher proportion at that position, and smaller letters (e.g., "T" at position 6) mean that the nucleotide has a lower proportion at that position.

[0028] FIG. 10 shows Cy5 signals collected from cells labeled with Cy5-modified RNA oligomers. Fig. 10A Shown are the mean fluorescence intensity (left y-axis, also referred to as "MFI") and the percentage of positively labeled cells (right y-axis) for both K562 cells and Jurkat cells. The experiment was repeated three times. K562 cells were labeled with RNA oligomers of varying concentrations, including 50 nM, 100 nM, 500 nM, and 1 μM. "NC" represents blank cells (no mgSrtA or RNA oligomers). Fig. 10B Shows Fig. 10A Multiple histograms of Cy5 fluorescence signals for one representative replicate out of the three replicates shown.The sequence of the RNA oligomer is shown in SEQ ID NO:3: G*G*G*GUGGGGCGGGGAAACACAUCCACUACCAACACUCUGCUUUAAGG*C*C*G, wherein "*" indicates phosphorothioate modification.

[0029] FIG. 11 shows FITC fluorescence signals collected from DNA sequences in various strand formats. Fig.11A FITC signals collected from three replicates are shown. Fig. 11B Shows Fig.11A Multiple histograms of FITC fluorescence signals for one representative replicate of the three replicates shown. For each format, the chain with a circle "F" represents a 45-nt DNA oligomer modified with FITC (denoted as "45*"). In the formats denoted as "45*+30RC" and "45*+45RC", the lower chain represents a DNA oligomer complementary to the 45* chain (the complementary chain of 30-nt or 45-nt is denoted as "30RC" or "45RC"). In the formats denoted as "45*+30" and "45*+45", the lower chain represents a DNA oligomer sharing the same sequence as 45*, except that the lower chain (denoted as "30" or "45") is not FITC modified. In each design of "45*+30RC", "45*+30", "45*+45RC" and "45*+45", the same mole of FITC-modified oligomer was mixed with another oligomer. In the designs denoted as 45* and 45, only single-stranded DNA oligomers with or without FITC modification were used, with no other DNA oligomers present.

[0030] The sequences of "45*" and "45" are shown in SEQ ID NO:4: ATCGATCGATGCTAGCTAGCGTTCAGACGTGTGCTCTTCCGATCT;

[0031] The sequence of "30RC" is shown in SEQ ID NO:5: ACGTCTGAACGCTAGCTAGCATCGATCGAT;

[0032] The sequence of "30" is shown in SEQ ID NO:6: ATCGATCGATGCTAGCTAGCGTTCAGACGT;

[0033] The sequence of “45RC” is shown in SEQ ID NO:7: AGATCGGAAGAGCACACGTCTGAACGCTAGCTAGCATCGATCGAT.

[0034] Fig.12 FITC signals collected from cells labeled with DNA sequences with different strand combinations are shown. The "cells only" column represents blank cells without the addition of mgSrtA and single-stranded or double-stranded DNA sequences; the other columns represent cells labeled with DNA oligos in the presence of mgSrtA. ss*: 20-nt (dark column) or 60-nt (grey column) FITC-modified DNA oligos; ss*+ss: two 20-nt (dark column) or two 60-nt (grey column) DNA oligos with the same sequence, but only one of the two 20-nt oligos or only one of the two 60-nt oligos is FITC-modified; ss*+ss(RC): 20-bp (dark column) or 60-bp (grey column) double-stranded DNA, one of which is modified with FITC.

[0035] The 20 nt "ss*" or "ss" sequence is shown in SEQ ID NO 8: ATCGATCGATGCTAGCTAGC;

[0036] The 20 nt "ss(RC)" sequence is shown in SEQ ID NO 9: GCTAGCTAGCATCGATCGAT;

[0037] The sequence of "ss*" or "ss" of 60 nt is shown in SEQ ID NO 10: ATCGATCGATCGATCTAGCGTTCAGACGTGTGCTCTTCCGATCTGTGAC TGGAGTTCAG;

[0038] The 60 nt "ss(RC)" sequence is shown in SEQ ID NO 11: CTGAACTCCAGTCACAGATCGGAAGAGCACACGTCTGAACGCTAGCTAG CATCGATCGAT.

[0039] Figure 13 shows phycoerythrin (PE) signals collected from cells labeled with biotin-modified PNA (peptide nucleic acid). The PE signal quantifies biotin through the affinity between biotin and streptavidin-PE antibody. Fig.13A It is shown that cells were labeled with PNA in the presence of mgSrtA. "Cells only" refers to blank cells prestained with streptavidin-PE antibody like other samples. Fig. 13B Displayed is a multi-histogram showing Fig.13A Fluorescence signal of one representative replicate from three replicate experiments. Fig. 13C The structure of PNA is shown.

[0040] Fig.14A Shown are confocal images showing the distribution of TAMRA signals on K562 cells labeled with TAMRA-modified DNA oligomers. Fig. 14B Shown are confocal images showing the distribution of FITC signals on K562 cells labeled with FITC-modified DNA oligomers. Fig. 14C Shown are confocal images showing the distribution of Cy5 signals on K562 cells labeled with Cy5-modified DNA oligomers. Fig.14A , 14B and 14C, from top to bottom, each row represents samples with ("+") or without (indicated as "-") the presence of mgSrtA and oligomers. TD: transmitted light detector. Oligonucleotide (+) concentration: 100 nM; mgSrtA (+) concentration: 20 μM. "Merge" refers to confocal images in which the fluorescence image (TAMRA, FITC, or Cy5) and the image captured under transmitted light (TD) were merged.

[0041] The sequence of the 3'-TAMRA-modified DNA oligomer is shown in SEQ ID NO 12: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHACTCACTTAAHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAAAAA;

[0042] The sequence of the 3'-FITC-modified DNA oligomer is shown in SEQ ID NO 13: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHAACATATCTCHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0043] The sequence of the 3′-Cy5 modified DNA oligomer is shown in SEQ ID NO 14: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHAACATATCTCHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA.

[0044] In the sequences of SEQ ID NOs: 12, 13 and 14, the letter H represents an A, C or T nucleotide, and the letter B represents a C, G or T nucleotide.

[0045] Fig.15A Confocal images shown demonstrate the distribution of TAMRA signals on Jurkat cells. Fig. 15B Confocal images shown show the distribution of FITC signal on Jurkat cells. Fig. 15C The confocal images shown show the distribution of Cy5 signals on Jurkat cells. Materials, annotations and test conditions are the same as in Figure 14.

[0046] Fig.16A Confocal images shown demonstrate the distribution of TAMRA signals on MC-38 cells. Fig. 16B Confocal images shown demonstrate the distribution of FITC signals on MC-38 cells. Fig. 16C The confocal images shown show the distribution of Cy5 signals on MC-38 cells. Materials, annotations and test conditions are the same as in Figure 14.

[0047] Fig.17A The western blot images shown show the reaction of two oligonucleotides with mgSrtA. The western blot showed that the intermediate product of mgSrtA and the biotin-modified oligomer was detected by anti-biotin antibody, indicating that the oligonucleotides reacted with mgSrtA under cell-free conditions. Fig. 17B The sequence and modifications of each oligonucleotide (O1, SEQ ID NO: 15 and O2, SEQ ID NO: 16) are shown.

[0048] Fig.18AThe bar graphs shown show the mean fluorescence intensity of K562 cells that were first treated with protease and then labeled with FITC-modified oligonucleotides. The first two columns represent blank cell controls (oligomer-, mgSrtA-) and no sortase controls (oligomer+, mgSrkA-). The "PBS" column represents samples that were not treated with protease but had sortase and oligomers present (oligomer+ and mgSrtA+). The experiment was repeated three times, and the error bars are represented as + / -1 standard deviation. Fig.18B Shows the Fig.18A Multiple histograms of FITC fluorescence signals from one representative replicate out of the three shown.

[0049] The sequence of the 3'-FITC modified oligonucleotide is shown in SEQ ID 17: GTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTNNNNNNNNNNNNBAA AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA.

[0050] In the sequence of SEQ ID NO: 17, the letter N represents an A, T, G or C nucleotide, and the letter B represents a C, G or T nucleotide.

[0051] Fig.19 The bar graphs shown show the mean fluorescence intensity of K562, Jurkat, and 293T cells treated with glycosidases in their respective enzyme reaction buffers and then labeled with oligonucleotides (SEQ ID NO: 14) in the presence of mgSrtA. A total of six sets of experiments were plotted. In each set, "NC", "HBSS buffer only" and / or "enzyme reaction buffer only" samples were included as controls and compared with other samples digested with different enzymes. The experiment included two steps: (1) a glycosidase digestion step and (2) a nucleic acid labeling step. In the glycosidase digestion step, in the "NC" and "HBSS buffer only" samples, cells were incubated in an HBSS buffer solution without digestion enzymes; and in the "enzyme reaction buffer only" sample, cells were incubated in an enzyme reaction buffer solution without digestion enzymes. In the labeling step, in the "HBSS buffer only" sample, cells were incubated with mgSrtA and oligonucleotides; but in the "NC" sample, no sortase and oligonucleotides were added. The sample of "enzyme reaction buffer only" was treated similarly to the sample of "HBSS buffer only", except that in step (1), the sample of "enzyme reaction buffer only" contained enzyme reaction buffer solution instead of HBSS buffer solution.

[0052] FIG20 shows multiple histograms of cells first treated with heparinase and then labeled with oligonucleotides in the presence of mgSrtA, showing Fig.19 One representative replicate of three experiments. Fig. 20A : K562 cells; Fig. 20B : Jurkat cells; Fig. 20C :293T cells. Other comments and Fig.19 Same as in.

[0053] FIG21 shows multiple histograms of cells first treated with chondroitinase ABC and then labeled with oligonucleotides in the presence of mgSrtA, showing Fig.19 One representative replicate of three experiments. Fig.21A : K562 cells; Fig.21B : Jurkat cells; Fig. 21C :293T cells. Other comments and Fig.19 Same as in.

[0054] FIG. 22 shows multiple histograms of cells that were first digested with a combination of heparinase and chondroitinase and then labeled with oligonucleotides in the presence of mgSrtA, showing Fig.19 One representative replicate of three experiments. Fig.22A : K562 cells; Fig. 22B : Jurkat cells; Fig. 22C :293T cells. Other comments and Fig.19 Same as in.

[0055] FIG23 shows multiple histograms of cells first digested with hyaluronidase and then labeled with oligonucleotides in the presence of mgSrtA, showing Fig.19 One representative replicate of three experiments. Fig.23A : K562 cells; Fig. 23B : Jurkat cells; Fig.23C :293T cells. Other comments and Fig.19 Same as in.

[0056] FIG24 shows multiple histograms of cells that were first digested with O-glycosidase or N-glycosidase F (PNGase F) and then labeled with oligonucleotides in the presence of mgSrtA, showing Fig.19 One representative replicate of three experiments. Fig.24A : K562 cells; Fig. 24B : Jurkat cells; Fig.24C :293T cells. Other comments and Fig.19 Same as in.

[0057] FIG25 shows multiple histograms of cells that were first digested with Protein Deglycosylation Mix II and then labeled with oligonucleotides in the presence of mgSrtA, showing Fig.19One representative replicate of three experiments. Fig.25A : K562 cells; Fig.25B : Jurkat cells; Fig.25C :293T cells. Other comments and Fig.19 Same as in.

[0058] FIG. 26 shows a comparison between wild-type SrtA and mgSrtA. Fig.26A , Fig.26B and Fig.26C The labeling efficiency of the oligomers and the effect of glycosidases are shown in the figure. Other annotations are similar to Fig.19 The amino acid sequence of wild-type SrtA is shown in SEQ ID NO: 18: KPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATPEQLNRGVSFAEENESLDDQNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRDVKPTDVGVLDEQKGKDKQLTLITCDDYNEKTGVWEKRKIFVATEVK.

[0059] Fig. 27 The bar graphs shown show the cell mean fluorescence intensity of K562 cells, Jurkat cells, Raji cells, 293T cells and Hela cells incubated with mgSrtA and oligonucleotides (left, SEQ ID NO: 14) or peptides (right). "NC" represents the incubation of cells, mgSrtA and oligomers. "PEG", "Heparin" and "ChonA Shark" represent the addition of 3000ng / μL PEG8000, 300ng / μL heparin and 300ng / μL chondroitin sulfate Shark, respectively. The oligonucleotides are Cy5 modified and the peptides are FITC modified. The peptide sequence is shown in SEQ ID NO: 19: AALPET*G (FITC-Ahx-AALPET-(2-hydroxyacetic acid)-G).

[0060] Fig.28 Multiple histograms of cells labeled with oligonucleotides (left, SEQ ID NO: 14) or peptides (right, SEQ ID NO: 19) in the presence of PEG, heparin, and ChonA Shark, respectively, are shown. Fig. 27A representative replicate of three replicate experiments for K562, Jurkat, Raji, 293T and Hela in . Oligonucleotides were Cy5 modified and peptides were FITC modified. "NC" represents incubation of cells, mgSrtA and oligonucleotides or peptides.

[0061] Fig.29 The bar graphs shown show the mean fluorescence intensity of cells incubated with mgSrtA and oligonucleotides (left, SEQ ID NO: 14) or peptides (right, SEQ ID NO: 19) in K562 cells, Jurkat cells, and 293T cells. "NC" represents incubation of cells, mgSrtA, and oligonucleotides or peptides. "Glucose", "Glycogen", "Heparin", and "ChonA Shark" represent the addition of 300 ng / μL glucose, 300 ng / μL glycogen, 300 ng / μL heparin, and 300 ng / u L of chondroitin sulfate Shark, respectively.

[0062] Fig.30 Multiple histograms of cells labeled with oligonucleotides (left, SEQ ID NO: 14) or peptides (right, SEQ ID NO: 19) in the presence of glucose, glycogen, heparin, and ChonA Shark, respectively, are shown. Fig.29 A representative replicate of three replicate experiments of K562 cells, Jurkat cells and 293T cells in Figure 1. Oligonucleotides were Cy5 modified and peptides were FITC modified. "NC" represents incubation of cells, mgSrtA and oligonucleotides or peptides.

[0063] The bar graph shown in Figure 31 shows the mean fluorescence intensity of cells incubated with (A) oligonucleotides (SEQ ID NO: 14) and (B) peptides (SEQ ID NO: 19). "NC" represents incubation of cells, mgSrtA and oligomers or peptides. "Heparin" and "heparan sulfate" represent the addition of 300ng / μL heparin and heparan sulfate, respectively. The oligonucleotides are Cy5 modified, and the peptides are FITC modified.

[0064] Figure 32 shows a bar graph and multiple histograms of signals showing the labeling efficiency of oligonucleotides (SEQ ID NO: 13) and peptides (SEQ ID NO: 19) between different cell lines. Figure 32A shows the normalized mean fluorescence intensity of oligonucleotides conjugated to K562, Jurkat, Raji, 293T, Hela, MC-38 and BaF3 cells. Figure 32B shows the normalized mean fluorescence intensity of peptides conjugated to these cells. Figures 32C and 32D show the fluorescence signal from a representative replicate of three replicate experiments.

[0065] Figure 33 shows a bar graph of oligonucleotide labeling of wild-type or multiple knockout cells. The x-axis refers to the genotype of the cell, and the y-axis refers to the labeling efficiency represented by the mean fluorescence intensity (MFI). Fig.33A ) and TAMRA( Fig.33B ) Two fluorescently modified oligonucleotides: a Cy5-modified oligonucleotide of SEQ ID NO: 14 and a TAMRA-modified oligonucleotide of SEQ ID NO: 12 were used.

[0066] Fig.34 An example of CellID oligonucleotide sequence design is shown. From the 5'-most end to the 3'-most end, the oligonucleotide contains a 22-nt anchor region enriched in guanine, a 35-nt PCR handle lacking in guanine, a 17-nt barcode region, and a capture sequence. The "capture sequence" can be designed as polyadenine (A) or other specific sequences (e.g., GCTTTAAGGCCG, from the capture sequence used by the 10X Genomics single-cell platform) that can be used to enrich for CellID sequences.

[0067] The sequence of 10X capture sequence 1 is shown in SEQ ID NO: 20: GCTTTAAGGCCG;

[0068] The sequence of 10X capture sequence 2 is shown in SEQ ID NO: 21: GCTCACCTATTAGC.

[0069] Fig.35 The bar graph shown shows the mean fluorescence intensity collected from cells labeled with oligonucleotide (SEQ ID NO: 13) in various buffers. The Y-axis of the column represents the mean value, and the error bars represent the standard deviation of three replicate experiments.

[0070] Fig.36A The line graphs shown show the mean fluorescence intensity collected from cells labeled with oligonucleotide (SEQ ID NO: 12) at different temperatures and different lengths of incubation time.The multiple histograms show the fluorescence signal of one representative replicate out of three replicate experiments performed in HBSS buffer. Fig.36B The displayed multi-histogram shows the Fig.36A Shown is one representative replicate of three labeling reactions performed at 4°C, RT and 37°C.

[0071] Fig.37 The bar graph shown shows the mean fluorescence intensity collected from cells labeled with the oligonucleotide (SEQ ID NO: 13) in PBS or HBSS buffer at different pH.

[0072] Fig.38The multihistograms shown show that the addition of different concentrations of Ca 2+ , does not affect Ca 2+ Dependent (SEQ ID NO: 2) or Ca 2+ Independent mgSrtA labeling efficiency of FITC-modified oligonucleotides.

[0073] Ca 2+ The amino acid sequence of the independent mgSrtA is shown in SEQ ID NO:22: KPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLNRGVSFAKENQSLDDQNISIAGHTFIGRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVGVLDEQKGKDKQLTLITCDDLNRETGVWETRKILVATEVK.

[0074] Fig.39A Line graphs showing the efficiency of cell labeling at different concentrations of EDTA are shown. The solid line and filled triangles represent the mean fluorescence intensity collected from cells labeled with an oligonucleotide (SEQ ID NO: 39) and then terminated with EDTA, with the intensity represented on the left y-axis. The dotted line and open triangles represent the percentage of positively labeled cells under the same conditions, with the percentage represented on the right y-axis. Different EDTA concentrations were tested, and Ca 2+ Dependence (SEQ ID NO: 2) and Ca 2+ Independent of two mgSrtA (SEQ ID NO: 22). Fig.39B The multi-histogram shown shows the Fig.39A Fluorescence signal from one representative replicate of three replicate experiments is shown.

[0075] Fig.40A Line graphs of cell labeling efficiency at different concentrations of oligonucleotides and peptides are shown, respectively. The solid line indicates the average fluorescence intensity at different oligonucleotide or peptide concentrations, and the intensity is represented on the left y-axis. The dotted line and hollow triangles indicate the percentage of positively labeled cells under the same conditions, and the percentage is represented on the right y-axis. Fig.40B The multi-histogram shown shows the Fig.40A The fluorescence signal of one representative replicate of three replicate experiments is shown in FIG. In these experiments, cells were first incubated with mgSrtA, and then oligonucleotides or peptides were added. The N-terminally biotinylated peptide (used in FIG. 40 ) is shown in SEQ ID NO: 23: AALPET*G, where “*” represents 2-hydroxyacetic acid.

[0076] The oligonucleotide with 3′-biotin (used in FIG. 40 ) is represented by SEQ ID NO: 24: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHCATCATCAATHHHHHGCTTTAAGG*C*C*G, wherein “*” indicates phosphorothioate.

[0077] Fig.41A Line graphs are shown showing the mean fluorescence intensity and percentage of positively labeled cells at different oligonucleotide concentrations. Fig.41B The multi-histogram shown shows the Fig.41A Fluorescence signal of one representative replicate of three replicates shown in . In these experiments, cells were first incubated with mgSrtA and then the oligonucleotides were added. Experiments were performed with K562 and Jurkat cell lines. The oligonucleotide of SEQ ID NO: 13 was used.

[0078] Fig.42A Line graphs of cell labeling efficiency at different concentrations of oligonucleotides (SEQ ID NO: 13) are shown respectively. The solid line represents the mean fluorescence intensity at different oligonucleotide concentrations, and the intensity is represented on the left y-axis. The dotted line and hollow triangle represent the percentage of positively labeled cells under the same conditions, and the percentage is represented on the right y-axis. Fig.42B The multi-histogram shown shows the Fig.42A Fluorescence signal from one representative replicate of three replicate experiments is shown in . In these experiments, cells, mgSrtA and oligonucleotides were incubated together.

[0079] Fig.43A Shown are line graphs comparing labeling signals between cells incubated with FITC-modified oligomers in the presence of mgSrtA (mgSrtA+) or in the absence of mgSrtA- (mgSrtA-). Both the mean fluorescence intensity (left y-axis) and the percentage of positively labeled cells (right y-axis) are shown. Fig.43B The multi-histogram shown shows the Fig.43A Fluorescence signal from one representative replicate of three replicate experiments is shown.

[0080] The oligonucleotide with 5′-FITC is shown in SEQ ID NO: 25: GGGGCGGGGTGGGGAAAGTGACTGGAGTTCAGACGTGTGCTCTTCCGATCTHHHAAGTTCAAGTTAGACHHHAGCTTTAAGGCCGGTCCTAGCAA.

[0081] Figure 44 shows a comparison of labeling efficiencies when different sortases or sortase mutants are used to label K562 cells. Fig.44A The average fluorescence intensity of the Cy5 signal from wild-type sortase (WT, SEQ ID NO: 18), 5M, Chen2016, and mgSrtA is shown. Fig.44B The multi-histogram shown shows the Fig.44A Fluorescence signal of one representative replicate of three replicates is shown in . The vertical line indicates the median of the three replicates. The oligonucleotide of SEQ ID NO: 14 was used.

[0082] The amino acid sequence of 5M is shown in SEQ ID NO:26: QAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLNRGVSFAEENESLDD QNISIAGHTFIDRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVEVLDEQKGKDKQLTLITCDDYNEETGVWETRKIFVATEVK;

[0083] The amino acid sequence of Chen2016 is shown in SEQ ID NO:27: KPHIDNYLHDKDKDEKIEQYDKNVKEQASKDKKQQAKPQIPKDKSKVAGYIEIPDADIKEPVYPGPATREQLNRGVSFAEENESLDDQNISIAGHTFIGRPNYQFTNLKAAKKGSMVYFKVGNETRKYKMTSIRNVKPTAVGVLDEQKGKDKQLTLITCDDLNRETGVWETRKIFVATEVK.

[0084] Figure 45 shows a line graph showing the fluorescent signal collected from cells labeled with oligonucleotide (SEQ ID NO: 14) and cultured for 120 hours. Two oligonucleotide concentrations (100 nM and 250 nM), and both mgSrtA+ and mgSrtA- were tested. Fig.45A The mean fluorescence intensity is shown, and Fig.45B The percentage of positively labeled cells is shown. The experiments were performed in triplicate and the mean and ± SD are indicated.

[0085] FIG46 shows a multiple histogram showing fluorescence signals at different time points during cell culture, which are from one representative replicate of the three replicate experiments shown in FIG45. Fig.46A Shown are signals collected from cells labeled with 100 nM oligonucleotides. Fig.46BShown are signals collected from cells labeled with 250 nM oligonucleotide.

[0086] Figure 47 shows confocal images of cells labeled with Cy5-oligomers during 120 hours of cell culture. K562 cells were cultured with 250 nM Cy5-modified ( Fig.47A ) or FITC-modified ( FIG. 47 / B ) oligonucleotide labeling. Fig.47A Images were collected at 0, 12, 24, 48, 72, 96, and 120 hours. Fig.47B The images were collected at 0 hr, 24 hr and 48 hr. Fig.47C The image is an orthogonal view of the signal collected 48 hours after the cells were labeled with Cy5-oligomers, where the cell membrane was stained with TRITC (tetramethylrhodamine). Orthogonal view is a commonly used image processing technique, where an object is observed from the xy plane, yz plane, and zx plane. Fig.47A and Fig.47C The oligonucleotide of SEQ ID NO: 14 was used, and Fig.47B The oligonucleotide of SEQ ID NO: 13 was used.

[0087] Fig.48 Shown the fluorescent image of 293T cell after 48 hours by GFP plasmid mark in the presence of mgSrtA.Plasmid carries GFP (green fluorescent protein) encoding sequence.Green fluorescence represents that plasmid is internalized in cell, and GFP protein is successfully expressed (white frame) in the cell by GFP plasmid mark.Three columns represent the images taken in the cells of different treatments, and two rows represent the photos taken from two microscope fields.

[0088] The sequence of the plasmid is shown in SEQ ID NO: 28:

[0089] Figure 49 shows a line graph showing the mean fluorescence intensity collected from different cell types after labeling with oligonucleotide (SEQ ID NO: 14). "Cells only" was included as a negative control. Fig.49A The mean fluorescence intensity of various primary cells is shown, and Fig.49B The mean fluorescence intensity of various immortalized cells is shown. The measurements were collected from three replicates.

[0090] Fig.50 The multiple histograms shown show the fluorescence signal of one representative replicate out of the three replicate experiments shown in FIG. 49 .

[0091] Fig.51 A schematic diagram of CellID labeling for a 10x single-cell RNA-seq (scRNA-seq) experiment is shown. In step I, "Labeling": cells in samples 1 to 3 are labeled with different CellID oligos, and each sample will carry a CellID with a unique sequence. In step II, "Merge", cells from different samples are merged. The merged cells are treated as a single sample and processed for scRNA-seq (e.g., 10x platform) in step 3. In step 3, "scRNA-seq", the cells are lysed, and the mRNA molecules are libraryed and sequenced. In this process, the CellID is also libraryed together with the mRNA molecules. In step 4, the resulting data is library split, and information from each sample is retrieved based on the characteristics of the respective CellIDs.

[0092] Fig.52 The CellIDs used in sample labeling for scRNA-seq experiments are listed. Each CellID represents a cell type. The species from which the cell line was derived is also listed.

[0093] The sequence CellID CA11 is shown in SEQ ID NO: 29: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHCATATCACTAHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0094] The sequence CellID CA12 is shown in SEQ ID NO:30: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHCATCATCAATHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0095] The sequence CellID CA13 is shown in SEQ ID NO:31: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHTATACACCATHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0096] The sequence CellID CA14 is shown in SEQ ID NO:32: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHACATTACTACHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0097] The sequence CellID CA15 is shown in SEQ ID NO:33: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHTCAACTACATHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0098] The sequence CellID CA16 is shown in SEQ ID NO:34: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHAACATATCTCHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0099] The sequence CellID CA17 is shown in SEQ ID NO:35: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHTACCATACATHHHHHBAAAAAAAAAAAAAAAAAAAAAAAAA AAA;

[0100] The sequence CellID CA18 is shown as SEQ ID NO:36: GGGGCGGGGTGGGGCGGGGAAATCATCTCAACCACTCACATCCACTACC AACACTCTHHACTCACTTAAHHHHHBAAAAAAAAAAAAAAAAAAAAA AAAA.

[0101] Fig.53The tSNE plot of an scRNA-seq experiment with multiplexed sequencing of eight samples is shown, including five human cell lines (293T, K562, HeLa, Jurkat, and A549) and three mouse cell lines (Hepa1-6, MC-38, and C2C12). Cells are clustered and annotated based on their gene expression profiles. In each panel, cells with a specific CellID are highlighted, and the name of the cell type is listed at the top of each panel. DETAILED DESCRIPTION OF THE INVENTION

[0102] All publications cited in this specification, including but not limited to patents and patent applications, are incorporated herein by reference as if fully set forth. If some of the contents of the references cited herein contradict or are inconsistent with the present disclosure, the present disclosure shall prevail.

[0103] Any embodiment of the present disclosure described herein, including those embodiments described only in a portion of the specification describing specific aspects of the present disclosure, and those embodiments described only in the examples or figures, may be combined with any other embodiment or embodiments, unless expressly denied or inappropriate. definition

[0104] It should be understood that the terminology used herein is only used to describe specific embodiments and is not intended to be limiting. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0105] Although any methods and materials similar or equivalent to those described herein can be used in the testing practice of the present disclosure, exemplary materials and methods are described herein.In describing and claiming the present disclosure, the following terminology is used.

[0106] In this specification and the appended claims, the singular forms "a," "an," and "the" include plural referents unless the content clearly dictates otherwise. Thus, for example, reference to "a cell" includes a combination of two or more cells, etc.

[0107] The terms "polynucleotide", "oligonucleotide", "oligomer", "nucleic acid" and "nucleic acid molecule" are used interchangeably herein and refer to a polymeric form of nucleotides of any length, either ribonucleotides or deoxyribonucleotides. The term refers only to the primary structure of the molecule. The polynucleotides disclosed herein can be modified with, for example, labeling groups such as fluorophores, biotin and thiophosphates. Such modified polynucleotides can be referred to as polynucleotide derivatives. Polynucleotide derivatives can contain modified purine or pyrimidine bases.

[0108] Polynucleotide derivatives include peptide nucleic acids. The terms "peptide nucleic acid," "oligo PNA," or "PNA" are used interchangeably herein to refer to polymers that are structurally similar to DNA or RNA. The backbone of a PNA is typically composed of repeating N-(2-aminoethyl)-glycine units linked by peptide bonds. Purine and pyrimidine bases or any modified species therein are linked to the backbone by bridges such as methylene bridges (-CH2-) and carbonyl (-(C=O)-). PNA is considered a derivative of nucleic acids.

[0109] The term "CellID" refers to an oligonucleotide sequence that can be used to mark cells, and cells marked with this can be identified by the characteristics of the oligonucleotide sequence attached to the cell and / or internalized in the cell. The term "CellID" can also refer to a method for marking cells using this oligonucleotide sequence design.

[0110] For example, "CellID" may refer to an oligonucleotide sequence design comprising a barcode of a random sequence. As another example, "CellID" may refer to an oligonucleotide sequence design comprising a barcode that does not contain a random sequence (ie, an oligonucleotide sequence design comprising a barcode of a non-degenerate sequence).

[0111] For example, the CellID oligonucleotide sequence comprises an anchor region, wherein the anchor region is preferably guanine-rich.

[0112] For example, from the most 5' end to the most 3' end, the CellID oligonucleotide sequence comprises an anchor region that can be attached to the cell membrane, a PCR handle for amplification, a programmable region (e.g., a barcode region) for distinguishing individual cells, and a capture sequence for oligomer enrichment. This CellID design can be used to identify cells, for example, by single-cell RNA-seq. Preferably, the CellID oligonucleotide sequence comprises an anchor region enriched in guanine (e.g., guanine accounts for more than 25% of nucleotides in the nucleotide sequence), a PCR handle lacking in guanine (e.g., guanine accounts for less than 25% of nucleotides in the nucleotide sequence), a programmable region (e.g., a barcode region) for distinguishing individual cells, and a capture sequence. The "capture sequence" can be designed as a polyadenine (A) sequence or other specific sequence (e.g., GCTTTAAGGCCG (SEQ ID NO: 19), a capture sequence used from the 10XGenomics single-cell platform), which can be used to enrich the CellID sequence.

[0113] "Barcoding" refers to the process of using a unique nucleotide sequence to label an entity, thereby identifying the entity. For example, "barcoding" can refer to the process of using a nucleic acid library of known sequences (nucleic acid barcodes) to label an unknown sample and matching the barcode sequence of the unknown sample with the barcode library for identification.

[0114] The terms "peptide", "polypeptide" and "protein" are used interchangeably herein and refer to a polymeric form of amino acids of any length, which may include coded and non-coded amino acids, chemically or biochemically modified or derivatized amino acids, and polypeptides with modified peptide backbones. These terms also include polypeptides with co-translational (e.g., signal peptide cleavage) and post-translational modifications of the polypeptide, such as disulfide bond formation, glycosylation, acetylation, phosphorylation, proteolytic cleavage, etc. The peptides disclosed herein can be modified with, for example, labeling groups such as fluorophores, biotin, His tags or thiophosphates.

[0115] In addition, as used herein, "polypeptide" refers to a protein that includes modifications to the native sequence, such as deletions, additions and substitutions (known to those skilled in the art and generally conservative in nature), as long as the protein retains the desired activity. These modifications may be intentional, such as through site-directed mutagenesis, or accidental, such as through mutations in the host that produces the protein, or due to errors caused by PCR amplification or other recombinant DNA methods.

[0116] The terms "polysaccharide", "oligosaccharide", "polycarbohydrate" or "glycan" are used interchangeably herein and refer to polymeric carbohydrates composed of monosaccharide units bound together by glycosidic bonds. Polysaccharides can range from linear to highly branched in structure. Examples of polysaccharides include glycosaminoglycans (GAGs), such as heparin, heparan sulfate proteoglycans (HSPGs), chondroitin sulfate proteoglycans (CSPGs), heparan sulfate, chondroitin sulfate or dermatan sulfate. Examples of polysaccharides also include storage polysaccharides, such as starch, glycogen and galactogen, and structural polysaccharides, such as cellulose and chitin. The term "glycan" can also be used to refer to the carbohydrate portion of a glycoconjugate, such as a glycoprotein (e.g., a glycoprotein comprising a GAG), a glycolipid or a proteoglycan. The term "polysaccharide" as used herein also includes modified forms, such as polysaccharides modified by another group, such as sulfation, carboxymethylation, acetylation and phosphorylation.

[0117] The term "subject" includes all animals, such as humans and other mammals.

[0118] The terms "labeling", "labeled" or "label" refer to the attachment of a detectable or identifiable group to an entity. For example, a protein, nucleic acid or polysaccharide can be labeled with a group such as a fluorophore, biotin, His tag or thiophosphate. For another example, a cell can be labeled with a nucleic acid (also referred to herein as "conjugated", "anchored", "linked" or "attached") by sortase catalysis. Subsequently, the nucleic acid can be internalized into the cell. A novel conjugation reaction mediated by sortase

[0119] The inventors have surprisingly discovered a novel conjugation reaction catalyzed by sortase, wherein nucleic acid or its derivative serves as a substrate for sortase, which catalyzes the attachment of nucleic acid to cells. In the presence of sortase, nucleic acid or its derivative can be attached to the plasma membrane of cells. Amino sugars associated with the plasma membrane, such as glycosaminoglycans (GAGs) or glycoproteins containing GAGs, can participate in this conjugation reaction.

[0120] Examples of GAGs include heparin, heparan sulfate proteoglycans (HSPG), chondroitin sulfate proteoglycans (CSPG), heparan sulfate, chondroitin sulfate and / or dermatan sulfate. Without wishing to be bound by theory, one or more polysaccharides that bind to the plasma membrane of the cell may act as anchoring factors, increase the local concentration of mgSrtA and / or the oligonucleotide, and thereby enhance the connection between the oligonucleotide and the plasma membrane.

[0121] In one embodiment, the disclosure provides a conjugate of a nucleic acid or a derivative thereof with a sortase. The disclosure also provides a conjugate of a nucleic acid and a cell.

[0122] The conjugation reaction can occur under conditions suitable for the sorting enzyme and / or cells. In one embodiment, the conjugation reaction occurs at 4°C to 40°C, such as 4°C to 37°C, 4°C to 25°C, or 18°C ​​to 25°C. In one embodiment, the conjugation reaction occurs at 4°C, room temperature, or 37°C.

[0123] The conjugation reaction may occur at a pH suitable for the sorting enzyme and / or the cells. In one embodiment, the conjugation reaction occurs at a pH of 4 to 8, such as 6 to 8, preferably 6.5 to 8.

[0124] In one embodiment, the conjugation reaction lasts about 1 to 30 minutes, such as 5-10 minutes or 5 to 20 minutes.

[0125] The sortase used in the conjugation reaction can be any sortase, such as any sortase disclosed herein. For example, the sortase can be sortase A, sortase B, and a variant of sortase A or sortase B. In one embodiment, the sortase is mgSrtA. In one embodiment, the sortase is selected from wild-type sortase, 5M sortase, Chen2016 sortase, and mgSrtA.

[0126] The nucleic acid or its derivative suitable for the conjugation reaction can be DNA or RNA, or a derivative of DNA or RNA. For example, the derivative can be a DNA or RNA modified with a labeling group (e.g., a fluorophore, biotin, or a thiophosphate). The derivative can also be a DNA or RNA containing a modified purine or pyrimidine base. In another example, the derivative can be a PNA or a derivative of a PNA.

[0127] Nucleic acids or derivatives thereof suitable for conjugation reactions may be double-stranded or single-stranded. Nucleic acids or derivatives thereof may be of any length, such as 1 to 4000 nucleotides, 4-500 nucleotides, 10-200 nucleotides, etc.

[0128] In one embodiment, the polynucleotide used in the conjugation reaction comprises a guanine-enriched sequence. For example, the guanine contained in the sequence accounts for more than 25%, such as 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100% of the nucleotides in the sequence.

[0129] The cells that can be used for the conjugation reactions disclosed herein can be any cells, such as bacterial cells, yeast cells, or any mammalian cells. The cells include any wild-type cells or any genetically modified cells, such as knockout cells.

[0130] Cell types suitable for conjugation reactions can have a wide range of characteristics, including cultured cells and primary cells. For example, the cell can be a primary cell or an immortalized cell. The cell can be a cancer cell line, a stem cell, a mouse spleen cell. Examples of primary cells include thymocytes, kidney cells, hepatocytes, lung cells, bone marrow cells or red blood cells. Examples of cells include K562 cells, Jurkat cells, 293T cells, Raji cells, Hela cells, MC-38 and BaF3.

[0131] In one embodiment, cells suitable for the conjugation reaction are cells in vivo, such as cells in a subject.

[0132] The conjugation reactions described herein can be performed in vitro or in vivo.

[0133] In one embodiment, the conjugation reaction is carried out by incubating a mixture of three components including nucleic acid, cells and sortase for an appropriate period of time, such as about 1 to 30 minutes. Any two of the three components may be included first, incubated for an appropriate period of time (such as 1 minute to 15 minutes), and then the third component may be added and incubated with the mixture of the first two components for another appropriate period of time (such as 1 minute to 15 minutes).

[0134] In one embodiment, the mixture of nucleic acids and cells is incubated at a temperature in the range of 4°C to 40°C for an appropriate period of time (e.g., 5 to 10 minutes), and then the sorting enzyme is added to the mixture, after which the resulting mixture is placed at a temperature in the range of 4°C to 40°C for another appropriate period of time (e.g., 5 to 10 minutes). This order of mixing polynucleotides, sorting enzymes, and cells is referred to as the "oligomer-1st" or "oligomer first" method. For example, in an "oligomer-1st" labeling experiment, 500,000 cells are first incubated with oligomers at 37°C for 5 minutes, and then mgSrtA is added to a final concentration of 20 μM and incubated at 37°C for another 10 minutes.

[0135] In one embodiment, the mixture of cells and sortase is incubated at a temperature in the range of 20°C to 40°C for an appropriate period of time (e.g., 5 to 10 minutes), and then the polynucleotide is added to the mixture, after which the resulting mixture is placed at a temperature in the range of 20°C to 40°C for another appropriate period of time (e.g., 5 to 10 minutes). This order of mixing cells, sortase, and polynucleotides is referred to as the "enzyme-1st" or "enzyme first" method. For example, in an "enzyme-1st" labeling experiment, 500,000 cells are first incubated with 20 μM mgSrtA at 37°C for 5 minutes, and then the oligomer is added and incubated at 37°C for another 10 minutes.

[0136] In one embodiment, the conjugation reaction is performed by incubating the mixture of cells, sortase and polynucleotides at a temperature ranging from 4° C. to 40° C. for an appropriate period of time (e.g., 1 to 30 minutes). This order of mixing cells, sortase and polynucleotides is referred to as the "concurrent" method.

[0137] In one embodiment, the ability to anchor nucleic acids or their derivatives to cell membranes provides a method for labeling cells with programmable nucleic acids or their derivatives (such as DNA, RNA or PNA). This method can be used to identify or barcode unique cells in a cell population or cell mixture. For example, cells can be barcoded using the CellID nucleic acids disclosed herein and then identified by sequencing (e.g., single cell RNA-seq).

[0138] In one embodiment, the nucleic acid connected to the cell membrane can then enter the cell. Therefore, the ability of nucleic acid or its derivatives to be anchored to the cell membrane can provide a method for delivering a nucleic acid drug or vaccine of gene therapy to a subject (such as a human patient). Nucleic acid drugs or vaccines can be designed to include a suitable anchoring region (e.g., a region enriched in guanine), which can be anchored to the cell membrane under the promotion of a sorting enzyme. This nucleic acid drug or vaccine can then enter the cell, and then play a therapeutic role, as shown in Figures 1-5. Sortase

[0139] The sortase used in the conjugation reaction disclosed herein can be any naturally occurring sortase or a functional variant thereof. Sorting enzymes refer to a group of proteins that modify surface proteins by recognizing and cleaving carboxyl-terminal sorting signals. For most substrates of sorting enzymes, the recognition signal consists of the motif LPXTG (Leu-Pro-any-Thr-Gly), followed by a highly hydrophobic transmembrane sequence, followed by a cluster of basic residues, such as arginine. Cleavage occurs between Thr and Gly, and the Thr residue is temporarily attached to the active site Cys residue, followed by a transpeptidation reaction that covalently attaches the protein to the cell wall component.

[0140] There are at least six types of sortases, including A, B, C, D, E and F sortases, as shown in the table below. 10 . Table 1. Species-specific sortase classes, substrates, and substrate recognition motifs

[0141] As described above, a variety of sortase variants have been developed, including the sortase variant (eSrtA, 5M) 6 、Srt7M 5 , Chen's team based on 5M variant evolution variants 7 , the “promiscuous” SrtA variant of the Chen group, mgSrtA 8 and the SrtA variant that recognizes LMVGG 9 .

[0142] In one embodiment, mgSrtA is used to covalently and operatively link a nucleic acid or a derivative thereof to the plasma membrane of a living cell. How to use

[0143] The discovery that nucleic acids or their derivatives can be attached to cells by sortase catalysis has a wide range of uses, for example, as research tools (such as barcoding cells) or for disease diagnosis or treatment (such as drug delivery). The following exemplifies barcoding and drug delivery methods using the conjugation reactions disclosed herein. Barcode marking

[0144] Nucleic acids or their derivatives can be attached to cells and provide an additional level of information for identifying the labeled cells, wherein the attached nucleic acids or their derivatives can be characterized and quantified by DNA sequencing (e.g., by high-throughput sequencing). This level of information can be used directly as a cell identifier. Such a cell identifier is referred to as a CellID oligonucleotide, or CellID for short. The term "CellID" can also refer to a method for labeling cells using such an oligonucleotide sequence design.

[0145] In one embodiment, the CellID oligonucleotide comprises a barcode sequence. For example, from the 5'-most end to the 3'-most end, the oligonucleotide sequence comprises an anchor region (e.g., 4 to 2000 nt, preferably 4-30 nt), a PCR handle (e.g., 18 to 40 nt), a barcode region (e.g., 1 to 50 nt, depending on the desired encoding complexity (which can be calculated as 4 n )) and capture sequence. For example, the anchor region can be 22-nt guanine-rich, the PCR handle can be 35-nt guanine-poor, and the barcode region can be 17nt. See Fig.34 . The "capture sequence" can be designed as polyadenine (A) or other specific sequences (for example, GCTTTAAGGCCG, the capture sequence used by the 10X Genomics single-cell platform), which can be used to enrich the CellID sequence. CellID information, together with other molecular phenotypes of cells, can be used to characterize cells. Other molecular phenotypes of cells include genomic DNA sequence, RNA expression levels, and DNA methylation profiles. Cell characterization can be performed at the population cell level or the single cell level. For example, multiple samples representing different treatment conditions can be labeled with their own oligonucleotides and mixed into a single sample for single-cell RNA-seq, such as Fig.51 This approach can eliminate batch effects (e.g., variation) between samples and reduce costs.

[0146] CellID oligonucleotides can also be used to label cells involved in certain biological processes in a certain area of ​​the body. For example, tumor infiltrating lymphocytes (TILs) can be labeled by injecting mgSrtA and different oligonucleotides into a tumor at multiple time points. The labeled TILs can be isolated by cell separation techniques (e.g., cell sorting) and analyzed for their presence at different time points. Drug delivery

[0147] By rapidly anchoring oligonucleotides to cell membranes, sortase-mediated oligonucleotide cell labeling can increase the local concentration of oligonucleotides at or around cells. Since the anchored oligonucleotides can then be internalized by cells, various forms of external nucleic acids or derivatives (e.g., nucleic acid drugs, vaccines, or bioconjugates comprising nucleic acids and therapeutic modules (such as small molecules or peptides)) can be effectively delivered to cells and participate in various downstream biological processes.

[0148] Figure 1 shows a comparison of the local distribution of nucleic acid drugs after local injection of the drug without (upper figure) or with (lower figure) sortase. As shown in the figure, before the nucleic acid drug molecules diffuse, the sortase rapidly catalyzes the conjugation between the nucleic acid drug and the cell membrane, resulting in the aggregation of nucleic acid drug molecules on the cell. When there is no sortase involved, the nucleic acid drug molecules diffuse out of the cell.

[0149] The injection sites applicable to gene therapy can be applied to the injection of sortase and nucleic acid drugs. As shown in Figure 2, nucleic acid drugs or their derivatives can be locally injected with sortase into a variety of sites, such as (A) tumor sites; (B) epidural sites; (C) intravitreal sites; or (D) intracerebral sites. Once the nucleic acid drug or its derivative enters the cell, it can exert a therapeutic effect, such as Figure 3-5 shown.

[0150] Nucleic acid drugs act as ligands to bind to intracellular receptors and transmit downstream signals 11-14 Internalized nucleic acid drugs can lead to downstream signal transduction and be sensed by a variety of intracellular receptors. For example, the receptors can be Toll-like receptors, cGAS or RIG-I, etc. ( Figure 3 ).

[0151] Nucleic acid drugs can work through sequence complementarity 15,16 . Nucleic acid drugs can exert their functions through sequence hybridization after being internalized into the cells to which they are conjugated. Figure 4 shows several examples of nucleic acid drugs and how they work. Figures 4A, 4B and 4C show that nucleic acid drugs hybridize with targeted mRNAs and cause degradation of targeted mRNAs. Figures 4D and 4E show that nucleic acid drugs act as steric blocking oligonucleotides to regulate the expression of targeted mRNAs without degrading mRNAs. Figure 4F shows that nucleic acid drugs can also target circular RNAs through sequence hybridization and cause degradation of circular RNAs.

[0152] Nucleic acid drugs can serve as mRNA templates to produce functional proteins 15,17 ( Figure 5 ).like Figure 5 As shown in , nucleic acid drug molecules are conjugated to the cell membrane under the promotion of sortase and then internalized into the cell. After being released into the cytoplasm, nucleic acid drugs can serve as mRNA templates and translate corresponding proteins. The resulting proteins can act as nuclear proteins to coordinate transcription programs, remain in the cytoplasm, be transported to the plasma membrane, or be presented to the outside of the cell by the MHC complex.

[0153] Nucleic acids can also be conjugated to circulating cells. In these cases, the circulating cells can serve as a transport vehicle through the body, and the conjugated oligonucleotide can serve as cargo for therapeutic purposes. 18The nucleic acid may itself be the drug, or may be part of a bioconjugate that contains a therapeutic moiety and serves as a vehicle for delivery.

[0154] The nucleic acid drugs disclosed herein can also be modified like other nucleic acid drugs to enhance favorable drug properties, such as delivery and persistence. Common modifications include chemical modifications, backbone modifications, nucleobase modifications, terminal modifications, ribose sugar modifications, bridged nucleic acids, and nucleic acid analogs (such as PNA) 15 . Example

[0155] The following examples are provided to describe the present disclosure in more detail. They are intended to illustrate rather than limit the present disclosure. Example 1: Cell culture

[0156] K562 and Jurkat were cultured in RPMI1640 (SigmaR8758) supplemented with 10% fetal bovine serum and 1% penicillin / streptomycin. 293T, Hela, A549, MC-38, Hepa1-6, and C2C12 were cultured in DMEM (Sigma D6429) supplemented with 10% fetal bovine serum (Gemini900-108) and 1% penicillin / streptomycin (Gibco15140-122). H1 was cultured in 1X mTeSR TM 1 Supplement (STEMCELL 85852) for mTeSR TM 1 basal medium (STEMCELL 85851). Example 2: Preparation of DNA oligomers, RNA oligomers and double-stranded DNA

[0157] Oligonucleotides were purchased from General Biol (Anhui, China), Genscript (Nanjing, China), and Genewiz (Suzhou, China). Peptides were purchased from Scilight Biotechnology (Beijing, China). Cy5-modified RNA oligomer powder was diluted with RNase-free H2O and stored in a -80°C refrigerator after aliquoting.

[0158] The FITC-modified 45-nt oligomer (indicated as 45* in FIG. 11 ) was mixed with an equimolar amount of its complementary chain or unmodified itself. The mixture was then heated at 95° C. for 5 minutes and returned to room temperature. In the presence of 20 μM mgSrtA, ssDNA, dsDNA, partial dsDNA, and ssDNA mixtures with a final concentration of 50 nM of the FITC-modified chain were incubated with 500,000 K562 cells at 37° C. for 10 minutes. Example 3: Sortase protein expression and purification

[0159] The wild-type sortase (SEQ ID NO: 18), mgSrtA (Ca 2+ Dependent, SEQ ID NO: 2), mgSrtA (Ca 2 + Independent, SEQ ID NO: 22) and Chen2016 (SEQ ID NO: 27) DNA sequences were cloned into a pET-28a backbone with an N-terminal 6xHis tag. The vector containing the DNA sequence 5M (SEQ ID NO: 26) was purchased from Addgene (Catalog No. 75144). The vector was transformed and expressed in Escherichia coli BL21 (DE3). When OD600 reached 0.6, IPTG (0.2mM) was added to each liter of Escherichia coli. The culture continued to grow overnight at 18°C ​​and then harvested by centrifugation. The cell mass was resuspended in 40mL lysis buffer (20mM Tris-HCl, pH7.8, 500mM NaCl) supplemented with protease inhibitors. The lysate was sonicated for 4 seconds with a half-inch probe on a Branson SFX550 at an amplitude of 35%, then left to stand for 4 seconds for 150 cycles. The solubilized lysate was centrifuged and the supernatant was filtered using a 0.45 μm filter (Millipore SLHVR33RB) and then loaded into a gravity column (Qiagen 1018244) with 2.5 mL Ni-NTA filler. The column was washed with 20 mL of wash buffer (20 mM Tris-HCl, pH 7.8, 500 mM NaCl, 40 mM imidazole) and the target protein was eluted with 40 mL of elution buffer (20 mM Tris-HCl, pH 7.8, 500 mM NaCl and 250 mM imidazole). Amicon Ultra-15 centrifugal filters can be used when small volumes are required. The purified protein was then stored at -80°C in 10% glycerol. Example 4: Cell labeling

[0160] In the presence of mgSrtA (20 mM), DNA, RNA or peptides were incubated with 500,000 cells in a 50 μL reaction at 37°C for 10 minutes. The concentration of DNA, RNA or peptide in the labeling reaction can be varied as desired. Exemplary substrate concentrations are 100 nM for DNA and RNA and 20 μM for peptides. The reaction was terminated with 50 mM EDTA.

[0161] In the "oligo-1st" labeling experiment, 500,000 cells were first incubated with oligos for 5 min at 37 °C, then mgSrtA was added to a final concentration of 20 μM and incubated for an additional 10 min at 37 °C.

[0162] In the "enzyme-1st" labeling experiment, 500,000 cells were first incubated with 20 μM mgSrtA at 37°C for 5 min, then oligos were added and incubated for an additional 10 min at 37°C. Example 5: Flow cytometry analysis

[0163] Prior to flow cytometry analysis, 500,000 cells were washed twice in 1 mL of cold PBS supplemented with 1% BSA. After washing, cells were resuspended in 200 μL of cold PBS and analyzed on a BC CytoFLEX LX. Example 6: SMART-seq library preparation

[0164] After the cell labeling reaction, the cells were washed three times with PBS. 500 cells were counted for both the labeled samples and the unlabeled control samples for Smart-Seq library preparation.

[0165] The Smart-Seq (TAKARA 634889) workflow protocol was followed before the amplified products of cDNA were purified. The supernatant from the 1X magnetic bead screening was collected and used for an additional 2X right magnetic bead screening. The product was then eluted in 12 μL of nuclease-free water.

[0166] To prepare the final library, 2 μL of the magnetic bead eluate was amplified in a 50 μL PCR reaction, which included 0.5 μL of 10 μM "dT primer", 0.5 μL of 10 μM "P7 primer", 22 μL of nuclease-free water and 25 μL NEBNext Ultra IIQ5 Master Mix (NEB M0544). The PCR reaction was performed for two rounds.

[0167] The first round of PCR reactions was performed under the following conditions: 98°C for 30 seconds, 10 or 12 cycles of 98°C for 10 seconds, 53°C for 30 seconds, and 72°C for 15 seconds (10 cycles for labeled samples, and 12 cycles for unlabeled control samples), and a final extension step of 72°C for 2 minutes. A total of five PCR reactions in this round were combined and concentrated with AmiconUltra 0.5ml 30kDa MWCO centrifugal filters (Millipore UFC5030BK), and purified and length-screened with 1.8X AMPureXP magnetic beads (Beckman A63882). The amplified products were eluted in 30 μL of nuclease-free water.

[0168] In the second round of PCR, 2 μL of template from the first round of PCR reaction was used in each 50 μL reaction, and the reaction included 25 μL of NEBNext Ultra IIQ5 Master Mix (NEB M0544), 0.5 μL of 10 μM "P5 primer", 0.5 μL of 10 μM "P7 primer" and 22 μL of nuclease-free water. The PCR program was set as follows: 98°C for 30 seconds, 8 cycles of 98°C for 10 seconds, 66°C for 30 seconds and 72°C for 20 seconds, and a final extension step of 72°C for 2 minutes. A total of 12 reactions in this round were combined and concentrated with an Amicon Ultra 0.5ml 30kDa MWCO centrifugal filter (Millipore UFC5030BK). The product was purified and length screened twice with 1.4X AMPure XP beads. dT Primer: 5'-CTACACGACGCTCTTCCGATCTatggtgagcaagggcgNNNNNNNNNNTTTTTTTTTTTTTTTTTTTTTTTTTTTTVN-3'(SEQ ID NO:37) P5 Primer: 5'-AATGATACGGCGACCACCGAGATCTACACTCTTTCCCTACACGAC GCTCTTCCG-3'(SEQ IDNO:38) P7 Primer: 5'-CAAGCAGAAGACGGCATACGAGATatatcagtGTGACTGGAGTTCAG ACGTGTGC-3'(SEQ IDNO:39) Example 7: Imaging

[0169] Collect cells and wash twice with PBS, then aliquot 500,000 cells into 50 μL HBSS per tube. In the presence of 20 μM mgSrtA, label cells at 37°C for 10 minutes with 100 nM oligonucleotides modified with FITC or TAMRA. At the end of incubation, wash cells twice with HBSS, then transfer cells to Nunc Lab Tek Chambered Coverglass (Thermo Scientific 155411) at a density of 20,000 cells in 300 μL HBSS per well. Take confocal images under FITC or TAMRA channels, laser power = 0.5. Example 8: Western Blot

[0170] DNA oligomers and mgSrtA were mixed and incubated at 37°C for 30 minutes. At the end of the incubation, the reaction was stopped by adding 1X loading dye and the samples were denatured at 95°C for 15 minutes. The mixture in the sample was then separated in 4-20% Bis-Tris PAGE (GenScript M00656) and transferred to a nitrocellulose membrane (Merck HATF00010). The membrane was blocked by incubation in 1X TBST (Sangon Biotech C520009-0500) containing 5% BSA and incubated with anti-biotin antibody (Abcam ab201341) diluted 1:500 in 5% BSA TBST buffer at room temperature for 2 hours or overnight at 4°C. The membrane was then washed three times with TBST and incubated with HRP-conjugated secondary antibody (Invitrogen 31430) diluted 1:5000 in 5% BSA TBST for 1 hour at room temperature. After washing three times with TBST, the membrane was developed using SuperSignalWest Pico PLUS (Thermo 34580). Example 9: Enzyme digestion and addition of GAGs

[0171] Prior to cell labeling, cells were incubated with proteases or glycosidases. 500,000 cells were used for enzymatic digestion in each 50 μL reaction. 1. Enzyme Digestion

[0172] Count 500,000 cells in total and treat with glycosidase or protease for 1 hour at an appropriate temperature. In some assays, more than one digestive enzyme (e.g., heparinase I / II / III combination) was used. At the end of the enzyme treatment, cells were pelleted by spinning at 500 g for 3 minutes and washed twice with 1 mL PBS. Cells were then incubated with 20 μM mgSrtA in HBSS at 37 ° C for 5 minutes, then oligonucleotides were added to a final concentration of 100 nM, and incubated for another 10 minutes at 37 ° C. 2. Addition of GAG

[0173] A total of 500,000 cells were incubated with 20 μM mgSrtA in the presence of 300 ng / μL glycosaminoglycans for 5 minutes at 37° C. After incubation, 100 nM oligomer or 20 μM peptide was added to the reaction and incubated for an additional 10 minutes at 37° C. Example 10: Study of Sortase-Mediated Nucleic Acid Reactions 1. Role of Oligonucleotides

[0174] We found that mgSrtA promotes oligonucleotide conjugation to cells. To investigate which type of nucleotide can be more favorably anchored to the cell membrane by mgSrtA catalysis, we compared the labeling efficiency of four oligonucleotides, each containing only one of the four nucleotides: 4-nt poly-G, 4-nt poly-C, 4-nt poly-A, and 4-nt poly-T, each modified with FITC. We labeled K562 cells with FITC-modified oligonucleotides in the presence of mgSrtA, with the absence of mgSrtA as a negative control (NC), and quantified the oligomer signal using flow cytometry ( Fig. 6A ). The results showed that 4-nt guanine oligomers (polyG) labeled the most cells and showed the highest intensity.

[0175] To exclude the possible influence of the fluorescent modifier, we repeated the same experiment using biotin-modified and TAMARA-modified 4-nt oligonucleotides. The results showed that mgSrtA-dependent cell labeling preferred guanine nucleotides ( Fig. 6A ).

[0176] We then increased the number of consecutive nucleotides to 32 nt and found that the reactivity of 32-nt polyadenine (poly A) was lower than that of the other oligos tested ( Figure 6B ). As we increased the oligomer length, 32-nt polycytosine (poly-C) showed good reactivity. 32-nt polythymine (poly-T) had some reactivity, but the labeling efficiency was lower than that of 4-nt poly-G ( Figure 6B ). Due to the limitation of nucleotide synthesis technology, 32-nt guanine oligomers were not included in the direct comparison. Under each treatment condition, the non-enzyme control (NC or mgSrtA-) showed that the labeling reaction was mgSrtA-dependent (Figures 6-7). These test results indicate that the labeling reaction is not a nonspecific binding between cells and oligonucleotides. In addition, the different activities of poly-G, poly-C, poly-A, and poly-T indicate that it may be the nitrogenous bases in the oligonucleotides that are mainly involved in the mgSrtA-mediated oligonucleotide labeling reaction, rather than carbon sugars or phosphates.

[0177] We further investigated nucleotide preference using a library screening assay. The library included oligonucleotides consisting of a 12-nt random sequence (12-nt barcode) for analysis of the nucleotide preference of mgSrtA. We also included PCR handles and poly A sequences surrounding the random sequence to incorporate into the SMART-seq library preparation strategy ( Figure 8). We incubated the oligonucleotide library with K562 cells in the presence (mgSrtA+) or absence (mgSrtA-) of mgSrtA. Oligonucleotides that successfully labeled K562 cells were enriched and analyzed by high-throughput sequencing (HTS). In the mgSrtA+ samples, guanine dominated the 12-nt random sequence region, especially in the first 11 nucleotide positions, while the nucleotide distribution between the 12-nt random sequence regions in the mgSrtA- samples was diverse ( Fig. 9 ). Results of library screening and HTS ( Figure 8-9 ) and the results of flow cytometry analysis (Figures 6-7) were well matched. These results indicate that mgSrtA prefers G-enriched oligomers.

[0178] To investigate whether nitrogenous bases are important in mgSrtA-dependent cell labeling, we investigated RNA oligomers in cell labeling experiments. We performed cell labeling experiments in K562 cells using different concentrations of Cy5-modified RNA oligomers. The results showed that RNA oligomers also successfully labeled cells in a mgSrtA-dependent manner, and the labeling efficiency was positively correlated with the RNA oligomer concentration (Figure 10). We repeated the experiment in Jurkat cells, and the labeling efficiency followed a similar pattern (Figure 10).

[0179] To further investigate the involvement of nitrogenous bases, we performed mgSrtA-dependent cell labeling using dsDNA, in which nitrogenous bases are paired and less reactive. We compared the labeling efficiency of different sequence configurations, including single-stranded DNA oligomers (ssDNA), double-stranded DNA (dsDNA), and partially double-stranded and partially single-stranded DNA. We prepared a 45-nt oligonucleotide with a 3'-FITC modification (referred to as 45*, where * indicates fluorescent modification, SEQ ID NO: 4).

[0180] Another set of oligonucleotides with different sequence lengths and different complementary lengths were premixed with 45*DNA at a 1:1 molar ratio. We included a 45-nt oligo (denoted as "45"), a 45-nt reverse complementary oligo (denoted as "45RC"), a 30-nt oligo (denoted as "30"), and a 30nt-reverse complementary oligo (denoted as "30RC"). The molar concentrations of the fluorescently modified oligonucleotides were the same between these samples.

[0181] Cells incubated with various oligomers were then analyzed by flow cytometry, and fluorescence was quantified to indicate the labeling efficiency of these different forms of the sequence. Compared to the equimolar single-stranded form 45*, the double-stranded form (45*+45RC) labeled cells much less efficiently, with a 76.7% decrease in mean fluorescence intensity (Figure 11). The same experiment was performed with oligomers of different sequence lengths (20nt (SEQ ID NO: 8) and 60nt (SEQ ID NO: 10)), and the results were consistent ( Fig.12 ).

[0182] We also tested the labeling efficiency of PNA. Biotinylated PNA was used to label K562 cells. The results showed that in the presence of mgSrtA, cells could be effectively labeled by PNA (Figure 13). PNA was purchased from NingBo Karebay Biochem, and the sequence is listed in Fig. 13C middle. 2. Cell Labeling by Oligonucleotides

[0183] We investigated the localization of the anchored oligonucleotides on the cell by imaging the labeled cells under confocal microscopy. Similar to typical transpeptidation reactions in Gram-positive bacteria, we found that the fluorescence signal of the fluorescently modified oligomers was localized on the cell membrane. These observations were consistent when the assay was performed with different fluorescently modified oligomers and tested in different cell lines (Figures 14-16). Although the fluorescence signal was diffuse on the cell membrane, the distribution of the signal was aggregated, indicating that the oligomers were not uniformly distributed on the cell membrane. 3. Conjugates of sortase and oligonucleotides

[0184] We also demonstrated in vitro the intermediates between mgSrtA and various oligonucleotides. We analyzed the intermediates between mgSrtA and two biotin-modified oligomers o1 (SEQ ID NO: 15) and o2 (SEQ ID NO: 16) under cell-free conditions by western blotting (Figure 17). The product bands also corresponded to the different lengths of the two oligonucleotides. 4. Role of components in cell membranes

[0185] We also investigated possible components on the cell membrane that are involved in the mgSrtA-catalyzed conjugation reaction with oligonucleotides.

[0186] In order to study whether proteins or carbohydrates in the cell membrane can participate in the bioconjugation with oligonucleotides catalyzed by sortase, we used different proteases and deglycosidases to destroy the protein and / or carbohydrate components on the plasma membrane. Cells were pretreated with digestive enzymes or enzyme combinations, and then oligonucleotide labeling was performed in the presence of mgSrtA. All proteases we tested resulted in a reduction in labeling efficiency of more than 50% (Figure 18). Among proteases, trypsin and proteinase K had the widest range of digestion substrates, and these two proteases resulted in a reduction in fluorescence intensity of more than 75%.

[0187] Next, we investigated whether the diverse and abundant glycosylation on proteins in the cell membrane contributes to the oligonucleotide labeling reaction. Most transmembrane proteins in animal cells are glycosylated. We included glycosidases that target both O-linked and N-linked glycans, as well as enzymes that specifically target glycosaminoglycans, including heparanase I / II / III, chondroitinase ABC, and hyaluronidase ( Fig.19 -25). The results showed that K562 cells digested with heparinase showed a loss of ∼50% fluorescence signal. Some heparinases also affected the labeling efficiency of Jurkat cells and 293T cells, but the effect was less than that of K562 cells. Chondroitinase ABC digestion resulted in a similar reduction in labeling efficiency in all three cell types, and the reduction was similar. We also noticed that the combined use of heparinase I / II / III and chondroitinase ABC greatly affected the labeling efficiency, retaining only 32.5% fluorescence.

[0188] We did not observe a decrease in labeling efficiency with hyaluronidase digestion, probably because hyaluronic acid has no protein core and is not sulfated. Similarly, PNGase F (which cleaves the innermost GlcNac and asparagine residues from N-linked glycoproteins) and O-glycosidase (which targets core 1 and core 3 O-linked disaccharides in glycoproteins) did not affect labeling as much as heparinase and chondroitinase. In addition, the use of the commercial NEB Deglycosidase Enzyme Mix II, which consists of five different glycosidases (including PNGase F, O-glycosidase, α2-3,6,8,9 neuraminidase A, β1-4 galactosidase S, and β-N-acetylhexosaminidase), did not significantly reduce labeling efficiency.

[0189] In addition, we compared the digestion efficiency of wild-type (WT) SrtA-mediated cell labeling with that of mgSrtA under the action of different enzymes. We found that under the conditions shown in Figures 26 and 44, the labeling efficiency of WT SrtA was lower than that of mgSrtA.

[0190] To confirm the involvement of glycosaminoglycans (GAGs) in SrtA-mediated oligonucleotide labeling of cell membranes, we tested several GAGs to investigate whether they would lead to reduced efficiency of cell labeling with oligomers. The addition of heparin, heparan sulfate, and chondroitin sulfate significantly affected oligonucleotide labeling of cells, whereas the addition of polyethylene glycol (PEG) did not reduce the efficiency ( Figure 27-28 ). These results were consistent across multiple cell types, including K562, Jurkat, Raji, HEK293T, and Hela cells, suggesting that GAGs may be involved in sortase-mediated oligonucleotide labeling of cells.

[0191] Furthermore, the addition of glucose and glycogen showed a similar pattern to that of PEG, indicating that they did not interfere with the reaction catalyzed by mgSrtA ( Figure 29-30 ). In addition, heparan sulfate had a stronger effect on cell labeling efficiency than heparin (Figure 31). These results together indicate that GAGs are involved in mgSrtA-mediated oligomer labeling of cell membranes.

[0192] We further investigated whether heparin, heparan sulfate, and / or chondroitin were involved in mgSrtA-mediated labeling of oligonucleotides on the cell membrane. We tested the heparan sulfate-negative cell line BaF3 and compared the labeling efficiency of BaF3 with that of other cell types. The results showed that BaF3 showed significantly lower labeling efficiency compared to the other six cell lines (K562, Jurkat, Raji, 293T, Hela, and MC-38) (Figure 32). Peptide labels showed a similar lack of labeling in BaF3, but to a lesser extent.

[0193] The results discussed above indicate that glycoproteins are involved in mgSrtA-mediated oligonucleotide labeling on the cell membrane. Next, we investigated whether blocking the biosynthetic enzymes of heparin, chondroitin, and proteoglycan core proteins would affect the conjugation between oligonucleotides and cell membranes. We constructed multiple knockout cell lines, each of which had a biosynthetic enzyme or a core protein that was disrupted. We compared the labeling efficiency between wild-type cells and these knockout cells, and found that knocking out EXT1 (exosome 1) reduced the labeling efficiency compared to knocking out other genes (Figure 33). These results support the involvement of GAGs in mgSrtA-mediated oligonucleotide cell labeling. Example 11: CellID labeling using oligonucleotides mediated by mgSrtA

[0194] As described above, sortase-dependent cell labeling with oligomers can be used for many applications. For example, it can be used to establish a sequence identifier for each individual cell. This method of labeling cells with oligonucleotides is referred to herein as CellID. To better serve this purpose, we optimized the oligomer sequences to achieve higher labeling efficiency and ease of characterization.

[0195] Compared with existing cell labeling methods (such as hashtag) 20 Similarly, CellID oligomers can include a PCR handle, a barcode region, and a capture sequence. The PCR handle and the capture sequence can facilitate downstream molecular biology processing to construct an NGS (next generation sequencing) library. The CellID oligomer can further include an anchor region, preferably guanine-enriched, for anchoring to the cell membrane. For example, the oligomer sequence used for CellID labeling preferably includes a guanine-enriched region for improving labeling efficiency, a PCR handle for amplification, a programmable region for distinguishing individual cells, and a capture sequence for oligomer enrichment (e.g., polyadenine (A) or a capture sequence from 10X Genomics, Fig.34 ).

[0196] We used 100 nM oligomer as a starting point to test labeling conditions, including reaction buffer type ( Fig.35 ), temperature (Figure 36) and pH value ( Fig.37 We tested various conditions compatible with cell-based assays and observed that CellID labeling was performed efficiently at 37°C in PBS or HBSS buffer (pH 6.5-8.0). We also noted that the addition of Ca 2+ No effect on Ca 2+ Dependent or Ca 2+ The labeling efficiency of mgSrtA-independent Fig.38 Other commonly used cell culture media with or without FBS were also used, but the labeling efficiency was lower than that in PBS or HBSS buffer ( Fig.35 ). The labeling reaction also occurred at relatively low temperatures, such as 4°C or room temperature (RT), but took longer (Figure 36). In addition, we also quantified the EDTA concentration used to terminate the labeling reaction to make CellID labeling more controllable. The results showed that labeling was effectively terminated with 30mM EDTA and that for Ca 2+ mgSrtA-dependent termination was more complete (Fig. 39).

[0197] We also titrated the oligonucleotide concentration to obtain the best labeling efficiency. We used a gradient concentration ranging from 10nM to 2μM in CellID labeling. In the first batch of concentration tests, we focused on the efficiency comparison when using oligonucleotides or peptides respectively. The results showed that the 86-nt oligonucleotide was more efficiently labeled to the cell membrane than the LPXTG peptide at the same molar concentration (Figure 40).

[0198] Next, we tested a second batch of concentrations for two different cell types. As the concentration of oligonucleotides increased, more than 90% of the cells were rapidly labeled at 50nM, and even at 2μM, the mean fluorescence intensity continued to increase (Figure 41). Interestingly, if cells were labeled with mgSrtA and oligonucleotides together (common method), rather than incubating the cells with mgSrtA first (enzyme-1st method), when the oligonucleotide concentration exceeded 500nM, the percentage of positively labeled cells decreased, indicating that high concentrations of oligonucleotides had an inhibitory effect (Figure 42). Flow cytometry results also showed that inhibition was not due to a decrease in cell viability.

[0199] In the concentration series experiment, a no-sortase control was also set for each concentration gradient. The results showed that the oligonucleotides did not label the cells without the sortase. Starting from 50 nM of the oligonucleotide, the labeling signal with the sortase was one order of magnitude higher than the corresponding no-sortase control, and when 1 μM of the oligonucleotide was applied, the labeling signal was two orders of magnitude higher than the control (Figure 43). Example 12: Cell labeling using oligonucleotides mediated by sortase variants

[0200] We compared the labeling ability of different sortases, including wild-type sortase and different mutants (Figure 44). Among the enzymes we tested, WT sortase, Chen2016 7 Both Chen2016 and mgSrtA showed labeling efficiency, although to varying degrees. Among them, WT sortase showed relatively weak but detectable labeling efficiency, about 1.5 times compared to the corresponding no-sortase control. Both Chen2016 and mgSrtA showed strong signals from the labeled oligonucleotides, 9 and 59 times that of the corresponding no-sortase control, respectively. Example 13: Retention and internalization of oligonucleotides in cells

[0201] We tested the retention time of the labeled oligonucleotides on the cell surface. After the initial oligonucleotide labeling, we cultured the cells for five consecutive days and measured fluorescence at multiple time points. 3'-Cy5 modified oligonucleotides were used to avoid degradation during the cell culture process. On day 5 (120 hours), almost all cells remained labeled with the oligonucleotides, as reflected by 100% of positively labeled cells (Figures 45-46). The mean fluorescence intensity decreased linearly with increasing culture time, with a decrease of approximately 4.4% at 4 hours and 14.4% at 24 hours. However, even at the last time point, the mean fluorescence of the labeled samples was still more than an order of magnitude higher than the no enzyme control, which was sufficient to distinguish the labeled cells from the negative control cells. The high signal-to-noise ratio (e.g., MFI of labeled cells compared to MFI of unlabeled cells) was high even at 120 hours. This observation shows that even at later time points, we can still distinguish the labeled cells from the background. This makes it possible for applications that require oligomers to label cells for longer periods of time.

[0202] In order to visualize the distribution of oligonucleotides in cells during cell culture, we also imaged the labeled cells at several time points. Surprisingly, we found that some oligomers entered the cells at the 12th hour time point. And at the later time points, almost all signals came from the inside of the cells (Figure 47). These observations show that oligonucleotides entered the cells under conventional culture conditions.

[0203] We also included a plasmid containing the GFP sequence in the cell labeling and internalization assays. Surprisingly, after 48 hours, GFP fluorescence was observed in 293T cells labeled with the GFP plasmid in the presence of mgSrtA ( Fig.48 ). These results suggest that cellular labeling with oligomers in the presence of sortase may provide new approaches to deliver and express plasmids or other external nucleic acids, such as drugs or vaccines, in vitro or in vivo in a subject. Example 14: Oligonucleotide labeling of multiple cell types

[0204] To expand the application, we also labeled various types of cell lines, including cancer cells and embryonic stem cells, as well as different types of primary cells with oligonucleotides (Figures 49-50). The cells tested came from different sources, including cancer cell lines, stem cells, mouse spleen cells, thymocytes, kidney cells, liver cells, lung cells, bone marrow cells, and red blood cells. These cells were effectively labeled with oligonucleotides, with a signal-to-noise ratio of at least two orders of magnitude compared to the no enzyme control. These results show that cell labeling with oligonucleotides can be applied to a variety of cell types. For example, labeling by CellID can be used as a universal cell labeling method. Example 15: CellID implements scRNA-seq of multiple samples

[0205] Bioconjugation between oligonucleotides and the plasma membrane can be used to link cell identity to nucleotide sequences, which can be easily characterized by high-throughput methods. We evaluated the performance of CellID in single-cell RNA-seq (scRNA-seq) of multiplexed samples. CellID labeling can be applied to multiple cell samples, and these cell samples can be analyzed simultaneously in a single experiment. This will eliminate batch effects and reduce the cost of scRNA-seq library preparation. For example, we labeled different types of cells with different CellID oligonucleotides and mixed them for scRNA-seq on the 10x platform, such as Fig.51 shown.

[0206] More specifically, to demonstrate the multiplex sequencing capability, we used eight different oligos (CellID: CA11 to CA18), and each oligo was used to label one cell line ( Fig.52 ). A total of five types of human cells and three types of mouse cells were labeled with their respective CellID oligos, and the labeled cells were then mixed. Since these cells were from different cell types and had different gene expression profiles, we investigated whether CellID could reconcile with the cell type classification inferred from single-cell transcriptome clustering. We used Seurat to generate clusters for 10,392 cells that went through the 10X standard data processing pipeline and visualized the cells in a tSNE plot ( Fig.53 ). Interestingly, each CellID projects to 1 or 2 clusters, and these projections are mutually exclusive across all CellIDs. We then annotated the tSNE clusters based on marker gene expression as well as CellID. The annotations from the two methods matched closely ( Fig.53 ), indicating that CellID accurately corresponds to cell type classification. Together, these results demonstrate the robustness of the CellID method to distinguish samples from different species, as well as samples from different cell sources of the same species. CellID enables simultaneous analysis of multiple samples in scRNA-seq experiments. More experimental details of the sample multiplexing are provided below. 1. Sample Preparation

[0207] Approximately 500,000 cells in each sample were pelleted by centrifugation at 500 g for 3 minutes. The pellets were washed twice with PBS and resuspended in 50 μL labeling buffer containing 100 nM oligonucleotide and 20 μM mgSrtA. The cells were incubated in labeling buffer at 37 ° C for 10 minutes, and the labeling reaction was terminated by adding 50 mM EDTA. The cells were then pelleted by centrifugation at 500 g for 3 minutes at 4 ° C and washed three times with 1 mL of cold PBS. In the first wash, 1% BSA and 30 mM EDTA were added to PBS, and then 0.04% BSA was added in the second and third washes. The cells were resuspended in PBS containing 0.04% BSA. Multiple samples were then combined in the desired ratio and 10xGenomics experiments were performed. During sample preparation, each test tube was pre-rinsed with 1 mL of PBS containing 1% BSA. After each round of washing, the supernatant was transferred to a new pre-rinsed test tube. 2. scRNA-seq library preparation

[0208] The 10x Genomics Single Cell 3'v3 workflow protocol was followed until the cDNA amplification step. PCR reactions were performed to amplify the labeled oligos as well as the cDNA of the labeled cells.

[0209] When using a labeled oligo that does not contain a 10x capture sequence at the 3' end (e.g., a labeled oligo that contains a poly A sequence as the capture sequence, called poly A CellID), add 0.5 μL of 2 μM "2.01st Nested PCR Primer" to the cDNA PCR mix. When using a labeled oligo that contains a 10x capture sequence at the 3' end (called CA CellID), add another 0.5 μL of 2 μM "Partial Read1N Primer". 2.0 1st nested PCR primer: 5'-CCACTCACATCCACTACCAACACT-3' (SEQ ID NO: 40). Partial Read1N primer: 5′-GCAGCGTCAGATGTGTATAAGAGACAG-3′ (SEQ ID NO: 41).

[0210] The cDNA amplified products were length screened using 0.6X AMPure XP magnetic beads, and the long fragments were subjected to cDNA library preparation to obtain the mRNA library according to the manufacturer's instructions.

[0211] For the supernatant of 0.6X magnetic bead sorting, add another 1.4X magnetic beads to enrich short fragments from the labeled oligomers. Wash the magnetic beads twice with 200μL 80% ethanol and elute in 40μL buffer EB (Qiagen 1014608). Use "P5 Sample index4bp primer" and "2.0P7 Read2index2 primer" to amplify the poly A CellID library, and use "P5Read1N primer" and "2.0P7 Read2index2 primer" to amplify the CA CellID library. PCR was performed in a 50μL volume including 5μL cDNA, 1.25μL of 10μM forward primer, 1.25μL of 10μM reverse primer, 17.5μL nuclease-free water and 25μL NEBNext Ultra IIQ5Master Mix (NEB M0544). PCR reactions were performed under the following conditions: 98°C for 30 seconds, 8-16 cycles of 98°C for 10 seconds, 55°C (poly A CellID) or 66°C (CA CellID) for 30 seconds and 72°C for 15 seconds, and a final extension step of 72°C for 2 minutes. The nucleotide library was purified using 1.2X SPRI magnetic beads. These steps generated the CellID library to be used for further analysis. P5 Sample index 4bp primer: 5'-AATGATACGGCGACCACCGAGATCTACACTAATCTTAACACTCTTTCCTACACGACGCTC-3' (SEQ ID NO: 42). P5 Read1N Primer: 5'-AATGATACGGCGACCACCGAGATCTACACTCGTCGGCAGCGT CAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 43). 2.0P7 Read2 index2 primer: 5'-CAAGCAGAAGACGGCATACGAGATCTATCGCTGTGACTGGAG TTCAGACGTGTGCTCTTCCGATCTTCACATCCACTACCAACACTCT-3' (SEQ ID NO: 44). 3. Calculation method

[0212] filter

[0213] We use cutadapt software 19Adapters were trimmed from the sequencing data and sequenced fragments without proper adapters were removed. Random barcode sequences were then extracted from the sequenced fragments and nucleotide frequencies were summarized.

[0214] 10x scRNA-seq

[0215] 10x scRNA-seq data were processed using Cell Ranger Single-Cell software. Sequence fragments from the mRNA library were aligned to the reference genome using default parameters. Sequence fragments from the CellID library were aligned to their own reference. Processed data from the CellID library and the mRNA library were merged according to the 10x cell barcode. Example 16: Summary of studies on oligonucleotide cell labeling mediated by sortase

[0216] The inventors surprisingly found that the oligonucleotides were conjugated to the cell membrane via a sortase, such as mgSrtA, which is a mutant of SrtA reported by Chen's group. 8 Sorting enzymes and their variants are thought to catalyze the transpeptidation reaction of peptides with sorting motifs (e.g., LPXTG) and nucleophilic substrates (e.g., N-oligoglycine). However, in our study, both DNA and RNA can be anchored to the cell membrane by sorting enzyme catalysis. To our knowledge, this is the first time that highly programmable nucleic acids have been efficiently labeled to the cell membrane.

[0217] To improve labeling efficiency, we used a screening assay and found that guanine is the preferred base for mgSrtA compared to other bases. We implemented an oligonucleotide design based on this finding, called CellID, and used it in tests under different reaction conditions. CellID technology can be used to label different cell types, such as primary and immortalized cells, in a short time (e.g., less than five minutes), with fluorescence intensity exceeding two orders of magnitude compared to controls without the sortase. The reaction conditions for efficient cell labeling can occur in conventional cell culture and living organisms, under conventional conditions such as temperature, culture medium, reaction buffer, and pH. The mild conditions under which oligomer-labeling occurs can promote the widespread application of labeling technology in biomedical research, disease diagnosis, and medical treatment.

[0218] We used enzymatic digestion and addition of different external molecules to identify the part that binds to the cell membrane that contributes to the conjugation of the oligonucleotide to the cell. Protease digestion had a negative impact on the oligomer labeling efficiency to varying degrees. Without wishing to be bound by this theory, because both chondroitin sulfate and heparin / heparan sulfate significantly affected the labeling efficiency, we believe that the abundant glycosaminoglycans (GAGs) in the cell membrane, especially heparin / heparan sulfate and chondroitin sulfate, are involved in the labeling reaction. The results of glycosidase digestion and addition of GAGs support this interpretation.

[0219] We also observed that 3'-Cy5 modified oligonucleotides entered cells during the cell culture process. Confocal images showed that some oligomers entered cells at 12 hours, and almost all oligomers entered cells at later time points, such as at 120 hours. This enables an attractive application to deliver nucleic acids or derivatives into cells. For example, nucleic acid drugs or vaccines can be delivered to subjects through sortase mediation. Nucleic acid anchors can also be conjugated to another therapeutic module (such as a peptide drug) and used as a vehicle to deliver the module to cells. Some somatic cells, such as lymphocytes, can be labeled with nucleic acid drugs or drugs with nucleic acid anchors in vitro or in vivo. Such labeled somatic cells can be carriers of nucleic acid drugs or drugs with nucleic acid anchors, and deliver drugs to multiple parts of the subject.

[0220] Previous studies have reported that heparan sulfate proteoglycans (HSPGs) and chondroitin sulfate proteoglycans (CSPGs) may be receptors or co-receptors for temporary attachment to the cell surface to facilitate the internalization of various macromolecules including DNA and viruses. 21 In our study, we demonstrated that GAGs were involved in oligomer labeling of cells based on the observation that heparinase and chondroitinase treatment reduced the oligomer labeling efficiency, and that the addition of heparin, heparan sulfate, and chondroitin sulfate also hampered oligomer labeling. Data from flow cytometric analysis further indicated that the internalization of oligonucleotides was affected by HSPGs and CSPGs.

[0221] The barcodes of CellID oligonucleotides are retained in CellID-labeled cells for five days or more. Therefore, CellID can be used as a robust cell labeling method. Higher initial concentrations of oligomers or chemical modifications (such as 2'-OMe or phosphorothioate) used to label cells may extend the retention time of oligomers in cells to some extent. Both the sequence and length of the oligomers can be flexibly designed.

[0222] In addition, easy and stable labeling of oligonucleotides on cell membranes allows adding programmable sequence information to cells, which can be decoded in later steps, such as sequencing by a sequencer. CellID labeling technology will enable diverse downstream applications in biological research and clinical applications.

[0223] Further embodiments are shown below. Embodiment 1. Conjugates of sortase and nucleic acids or their derivatives. Embodiment 2. The conjugate of embodiment 1, wherein the sortase is selected from sortase A, sortase B and variants thereof. Embodiment 3. The conjugate of any one of embodiments 1-2, wherein the sortase is mgSrtA. Embodiment 4. Conjugates of cells and nucleic acids or their derivatives. Embodiment 5. The conjugate of embodiment 4, wherein the nucleic acid or derivative thereof is conjugated to the plasma membrane of the cell. Embodiment 6. The conjugate of any one of embodiments 4-5, wherein the cells are selected from primary cells and immortalized cells. Embodiment 7. The conjugate of any one of embodiments 1-6, wherein the nucleic acid or derivative thereof is selected from the group consisting of DNA, RNA and PNA. Embodiment 8. The conjugate of any one of embodiments 1-7, wherein the nucleic acid or derivative thereof is single-stranded. Embodiment 9. A nucleic acid or a derivative thereof comprising an anchor region, wherein the anchor region is guanine-rich. Embodiment 10. A nucleic acid or a derivative thereof comprising an anchor region, a region for PCR amplification, a barcode region for identification, and a capture sequence for sequence enrichment. Embodiment 11. The nucleic acid or derivative thereof of embodiment 10, wherein the anchor region is enriched in guanine, the region for PCR amplification is guanine-poor, and the capture sequence is a poly A sequence or a capture sequence suitable for high-throughput sequencing. Embodiment 12. The conjugate of any one of embodiments 1-8, wherein the nucleic acid or derivative thereof is the nucleic acid or derivative thereof of any one of embodiments 9-11. Embodiment 13. A method for preparing a conjugate of a cell and a nucleic acid or a derivative thereof, comprising contacting a nucleic acid or a derivative thereof, a cell and a sortase, wherein the nucleic acid or a derivative thereof is conjugated to the cell, and wherein the conjugation of the nucleic acid or a derivative thereof to the cell is catalyzed by the sortase. Embodiment 14. The method of embodiment 13, wherein the cells are selected from primary cells and immortalized cells. Embodiment 15. The method of any one of embodiments 13-14, wherein the nucleic acid or derivative thereof is conjugated to the plasma membrane of the cell. Embodiment 16. The method of any one of embodiments 13-15, wherein glycosaminoglycans associated with cell membranes participate in the conjugation reaction. Embodiment 17. The method of embodiment 16, wherein the glycosaminoglycan is selected from the group consisting of heparin, heparan sulfate, chondroitin sulfate, and dermatan sulfate. Embodiment 18. The method of any one of embodiments 13-17, wherein the sortase is selected from sortase A, sortase B, and variants thereof. Embodiment 19. The method according to any one of embodiments 13-18, wherein the sortase is mgSrtA. Embodiment 20. The method of any one of embodiments 13-19, wherein the nucleic acid or its derivative is selected from the group consisting of DNA, RNA and PNA. Embodiment 21. The method according to any one of embodiments 13-20, wherein the nucleic acid or derivative thereof is single-stranded. Embodiment 22. The method of any one of embodiments 13-21, wherein the nucleic acid or derivative thereof is the nucleic acid or derivative thereof of any one of embodiments 9-11. Embodiment 23. The method of any one of embodiments 13-22, wherein the conjugation reaction occurs in vitro or in vivo. Embodiment 24. The method of any one of embodiments 13-23, wherein the cell is first contacted with the nucleic acid or a derivative thereof and then contacted with the sortase. Embodiment 25. The method of any one of embodiments 13-23, wherein the cell is first contacted with the sortase and then with the nucleic acid or derivative thereof. Embodiment 26. The method of any one of embodiments 13-25, wherein the conjugation reaction occurs in vitro in a reaction medium, and wherein the nucleic acid or derivative thereof is present in the reaction medium at a concentration ranging from about 1 nM to about 10 μM. Embodiment 27. The method of Embodiment 26, wherein the contacting is performed at about 4°C to about 40°C. Embodiment 28. The method of any one of Embodiments 26-27, wherein the contacting is performed for about 1 minute to 30 minutes. Embodiment 29. The method of any one of embodiments 26-28, further comprising terminating the conjugation reaction of the nucleic acid or its derivative with the cell after about 1 minute to 30 minutes of contact. Embodiment 30. A method of delivering a nucleic acid or a derivative thereof to a cell, comprising providing a nucleic acid or a derivative thereof and a sortase to the vicinity of the cell, wherein the nucleic acid or a derivative thereof is conjugated to the cell by catalysis of the sortase, and wherein the nucleic acid or a derivative thereof is subsequently internalized into the cell. Embodiment 31. The method of embodiment 30, wherein the method is performed in vivo or in vitro. Embodiment 32. The method of any one of embodiments 30-31, wherein the nucleic acid or derivative thereof comprises a drug. Embodiment 33. The method of any one of Embodiments 31-32, wherein the nucleic acid or derivative thereof comprises a vaccine. Embodiment 34. The method of any one of embodiments 30-33, wherein the sortase is selected from sortase A, sortase B, and variants thereof. Embodiment 35. The method according to any one of embodiments 30-34, wherein the sortase is mgSrtA. Embodiment 36. A method for barcoding a cell, comprising: contacting a nucleic acid or a derivative thereof, a cell, and a sortase, wherein the nucleic acid or a derivative thereof is conjugated to the cell, wherein the conjugation reaction of the nucleic acid or a derivative thereof to the cell is catalyzed by the sortase, and wherein the nucleotide or a derivative thereof comprises the nucleic acid or a derivative thereof of any one of embodiments 9 to 11; and The cells are identified by determining the identity of the nucleic acid or derivative conjugated to the cells. Embodiment 37. The method of embodiment 36, wherein the method is performed in vivo or in vitro. Embodiment 38. The method of any one of embodiments 36-37, wherein the cells are selected from primary cells and immortalized cells. Embodiment 39. The method of any one of embodiments 36-38, wherein the sortase is selected from sortase A, sortase B, and variants thereof. Embodiment 40. The method according to any one of embodiments 36-39, wherein the sortase is mgSrtA. Embodiment 41. The method of any one of embodiments 36-40, wherein the identity of the nucleic acid or derivative conjugated to the cell is determined by high-throughput sequencing. Embodiment 42. A kit comprising a sortase and a nucleic acid or a derivative thereof. Embodiment 43. The kit of embodiment 42, wherein the nucleic acid or derivative thereof is the nucleic acid or derivative thereof of any one of embodiments 9-11.

[0224] While the present disclosure has been particularly shown and described with reference to particular embodiments, it will be understood by those skilled in the art that various changes in form and details may be made without departing from the spirit and scope of the present disclosure disclosed herein. References 1.Jacobitz,A.W.,Kattke,M.D.,Wereszczynski,J.&Clubb,R.T.SortaseTranspeptidases:Structural Biology and Catalytic Mechanism.Adv Protein ChemStruct Biol 109,223-264(2017). 2.Pishesha,N.,Ingram,J.R.&Ploegh,H.L.Sortase A:A Model forTranspeptidation and Its Biological Applications.Annu Rev Cell Dev Biol 34,163-188(2018). 3.Samantaray,S.,Marathe,U.,Dasgupta,S.,Nandicoori,V.K.&Roy,R.P.Peptide-sugar ligation catalyzed by transpeptidase sortase:a facileapproach to neoglycoconjugate synthesis.J Am Chem Soc 130,2132-2133(2008). 4.Bellucci,J.J.,Bhattacharyya,J.&Chilkoti,A.A noncanonical functionof sortase enables site-specific conjugation of small molecules to lysineresidues in proteins.Angew Chem Int Ed Engl 54,441-445(2015). 5.Glasgow,J.E.,Salit,M.L.&Cochran,J.R.In Vivo Site-Specific ProteinTagging with Diverse Amines Using an Engineered Sortase Variant.J Am Chem Soc138,7496-7499(2016). 6.Chen,I.,Dorr,B.M.&Liu,D.R.A general strategy for the evolution ofbond-forming enzymes using yeast display.Proc Natl Acad Sci U S A 108,11399-11404(2011). 7.Chen,L.et al.Improved variants of SrtA for site-specificconjugation on antibodies and proteins with high efficiency.Sci Rep 6,31899(2016). 8.Ge,Y.et al.Enzyme-Mediated Intercellular Proximity Labeling forDetecting Cell-Cell Interactions.J Am Chem Soc 141,1833-1837(2019). 9.Podracky,C.J.et al.Laboratory evolution of a sortase enzyme thatmodifies amyloid-beta protein.Nat Chem Biol 17,317-325(2021). 10.Bradshaw,W.J.et al.Molecular features of the sortase enzymefamily.FEBS J 282,2097-2114(2015). 11.Li,Q.,Ren,J.,Liu,W.,Jiang,G.&Hu,R.CpG OligodeoxynucleotideDeveloped to Activate Primate Immune Responses Promotes Antitumoral Effectsin Combination with a Neoantigen-Based mRNA Cancer Vaccine.Drug Des DevelTher15,3953-3963(2021). 12.Juliano,R.L.The delivery of therapeutic oligonucleotides.NucleicAcids Res 44,6518-6548(2016). 13.Yang,H.,Wang,H.,Ren,J.,Chen,Q.&Chen,Z.J.cGAS is essential forcellular senescence.Proc Natl Acad Sci U S A 114,E4612-E4620(2017). 14.Kell,A.M.&Gale,M.,Jr.RIG-I in RNA virus recognition.Virology 479-480,110-121(2015). 15.Roberts,T.C.,Langer,R.&Wood,M.J.A.Advances in oligonucleotide drugdelivery.Nat Rev Drug Discov 19,673-694(2020). 16.Kole,R.,Krainer,A.R.&Altman,S.RNA therapeutics:beyond RNAinterference and antisense oligonucleotides.Nat Rev Drug Discov 11,125-140(2012). 17.Pardi,N.,Hogan,M.J.,Porter,F.W.&Weissman,D.mRNA vaccines-a new erain vaccinology.Nat Rev Drug Discov 17,261-279(2018). 18.Shi,J.et al.Engineered red blood cells as carriers for systemicdelivery of a wide array of functional probes.Proc Natl Acad Sci U S A 111,10131-10136(2014). 19. Martin, M. Cutadapt Removes Adapter Sequences From High-ThroughputSequencing Reads. EMBnet 17 (2011). 20. Stoeckius, M. et al. Cell Hashing with barcoded antibodies enables multiplexing and doublet detection for single cell genomics. Genome Biol 19, 224 (2018). 21. Park, H. et al. Heparan sulfate proteoglycans (HSPGs) and chondroitinsulfate proteoglycans (CSPGs) function as endocytic receptors for aninternalizing anti-nucleic acid antibody. Sci Rep 7, 14373 (2017). Sequence Listing <110> WESTLAKE UNIVERSITY <120> Conjugate of nucleic acid or its derivative and cell, preparation method and use thereof <130> IEC216057PCT <160> 44 <170> PatentIn version 3.5 <210> 1 <211> 34 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 1 gtgactggag ttcagacgtg tgctcttccg atct 34 <210> 2 <211> 181 <212> PRT <213> Artificial sequence <220> <223> mgSrtA <400> 2 Lys Pro His Ile Asp Asn Tyr Leu His Asp Lys Asp Lys Asp Glu Lys 1 5 10 15 Ile Glu Gln Tyr Asp Lys Asn Val Lys Glu Gln Ala Ser Lys Asp Lys 20 25 30 Lys Gln Gln Ala Lys Pro Gln Ile Pro Lys Asp Lys Ser Lys Val Ala 35 40 45 Gly Tyr Ile Glu Ile Pro Asp Ala Asp Ile Lys Glu Pro Val Tyr Pro 50 55 60 Gly Pro Ala Thr Arg Glu Gln Leu Asn Arg Gly Val Ser Phe Ala Glu 65 70 75 80 Glu Asn Glu Ser Leu Asp Asp Gln Asn Ile Ser Ile Ala Gly His Thr 85 90 95 Phe Ile Gly Arg Pro Asn Tyr Gln Phe Thr Asn Leu Lys Ala Ala Lys 100 105 110 Lys Gly Ser Met Val Tyr Phe Lys Val Gly Asn Glu Thr Arg Lys Tyr 115 120 125 Lys Met Thr Ser Ile Arg Asn Val Lys Pro Thr Ala Val Gly Val Leu 130 135 140 Asp Glu Gln Lys Gly Lys Asp Lys Gln Leu Thr Leu Ile Thr Cys Asp 145 150 155 160 Asp Leu Asn Arg Glu Thr Gly Val Trp Glu Thr Arg Lys Ile Leu Val 165 170 175 Ala Thr Glu Val Lys 180 <210> 3 <211> 50 <212> RNA <213> Artificial sequence <220> <223> Artificial sequence <400> 3 gggguggggc ggggaaacac auccacuacc aacacucugc uuuaaggccg 50 <210> 4 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 4 atcgatcgat gctagctagc gttcagacgt gtgctcttcc gatct 45 <210> 5 <211> 30 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 5 acgtctgaac gctagctagc atcgatcgat 30 <210> 6 <211> 30 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 6 atcgatcgat gctagctagc gttcagacgt 30 <210> 7 <211> 45 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 7 agatcggaag agcacacgtc tgaacgctag ctagcatcga tcgat 45 <210> 8 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 8 atcgatcgat gctagctagc 20 <210> 9 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 9 gctagctagc atcgatcgat 20 <210> 10 <211> 60 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 10 atcgatcgat gctagctagc gttcagacgt gtgctcttcc gatctgtgac tggagttcag 60 <210> 11 <211> 60 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 11 ctgaactcca gtcacagatc ggaagagcac acgtctgaac gctagctagc atcgatcgat 60 <210> 12 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 12 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactctha 60 ctcacttaah hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 13 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 13 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactctha 60 acatatctch hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 14 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 14 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactctha 60 acatatctch hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 15 <211> 4 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 15 gggg 4 <210> 16 <211> 20 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 16 ggggcggggt ggggcggggt 20 <210> 17 <211> 79 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <220> <221> misc_feature <222> (35)..(46) <223> n is a, c, g, or t <400> 17 gtgactggag ttcagacgtg tgctcttccg atctnnnnnn nnnnnnbaaa aaaaaaaaaa 60 aaaaaaaaaaaa aaaaaaaa 79 <210> 18 <211> 181 <212> PRT <213> Staphylococcus aureus <400> 18 Lys Pro His Ile Asp Asn Tyr Leu His Asp Lys Asp Lys Asp Glu Lys 1 5 10 15 Ile Glu Gln Tyr Asp Lys Asn Val Lys Glu Gln Ala Ser Lys Asp Lys 20 25 30 Lys Gln Gln Ala Lys Pro Gln Ile Pro Lys Asp Lys Ser Lys Val Ala 35 40 45 Gly Tyr Ile Glu Ile Pro Asp Ala Asp Ile Lys Glu Pro Val Tyr Pro 50 55 60 Gly Pro Ala Thr Pro Glu Gln Leu Asn Arg Gly Val Ser Phe Ala Glu 65 70 75 80 Glu Asn Glu Ser Leu Asp Asp Gln Asn Ile Ser Ile Ala Gly His Thr 85 90 95 Phe Ile Asp Arg Pro Asn Tyr Gln Phe Thr Asn Leu Lys Ala Ala Lys 100 105 110 Lys Gly Ser Met Val Tyr Phe Lys Val Gly Asn Glu Thr Arg Lys Tyr 115 120 125 Lys Met Thr Ser Ile Arg Asp Val Lys Pro Thr Asp Val Gly Val Leu 130 135 140 Asp Glu Gln Lys Gly Lys Asp Lys Gln Leu Thr Leu Ile Thr Cys Asp 145 150 155 160 Asp Tyr Asn Glu Lys Thr Gly Val Trp Glu Lys Arg Lys Ile Phe Val 165 170 175 Ala Thr Glu Val Lys 180 <210> 19 <211> 7 <212> PRT <213> Artificial sequence <220> <223> Artificial sequence <400> 19 Ala Ala Leu Pro Glu Thr Gly 1 5 <210> 20 <211> 12 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 20 gctttaaggc cg 12 <210> twenty one <211> 14 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> twenty one gctcacctat tagc 14 <210> twenty two <211> 181 <212> PRT <213> Artificial sequence <220> <223> Artificial sequence <400> twenty two Lys Pro His Ile Asp Asn Tyr Leu His Asp Lys Asp Lys Asp Glu Lys 1 5 10 15 Ile Glu Gln Tyr Asp Lys Asn Val Lys Glu Gln Ala Ser Lys Asp Lys 20 25 30 Lys Gln Gln Ala Lys Pro Gln Ile Pro Lys Asp Lys Ser Lys Val Ala 35 40 45 Gly Tyr Ile Glu Ile Pro Asp Ala Asp Ile Lys Glu Pro Val Tyr Pro 50 55 60 Gly Pro Ala Thr Arg Glu Gln Leu Asn Arg Gly Val Ser Phe Ala Lys 65 70 75 80 Glu Asn Gln Ser Leu Asp Asp Gln Asn Ile Ser Ile Ala Gly His Thr 85 90 95 Phe Ile Gly Arg Pro Asn Tyr Gln Phe Thr Asn Leu Lys Ala Ala Lys 100 105 110 Lys Gly Ser Met Val Tyr Phe Lys Val Gly Asn Glu Thr Arg Lys Tyr 115 120 125 Lys Met Thr Ser Ile Arg Asn Val Lys Pro Thr Ala Val Gly Val Leu 130 135 140 Asp Glu Gln Lys Gly Lys Asp Lys Gln Leu Thr Leu Ile Thr Cys Asp 145 150 155 160 Asp Leu Asn Arg Glu Thr Gly Val Trp Glu Thr Arg Lys Ile Leu Val 165 170 175 Ala Thr Glu Val Lys 180 <210> 23 <211> 7 <212> PRT <213> Artificial Sequence <220> <223> Artificial Sequence <400> 23 Ala Ala Leu Pro Glu Thr Gly 1 5 <210> twenty four <211> 86 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> twenty four ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactcthhc 60 atcatcaath hhhhgcttta aggccg 86 <210> 25 <211> 95 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 25 ggggcggggt ggggaaagtg actggagttc agacgtgtgc tcttccgatc thhhaagttc 60 aagttagach hhagctttaa ggccggtcct agcaa 95 <210> 26 <211> 147 <212> PRT <213> Artificial sequence <220> <223> Artificial sequence <400> 26 Gln Ala Lys Pro Gln Ile Pro Lys Asp Lys Ser Lys Val Ala Gly Tyr 1 5 10 15 Ile Glu Ile Pro Asp Ala Asp Ile Lys Glu Pro Val Tyr Pro Gly Pro 20 25 30 Ala Thr Arg Glu Gln Leu Asn Arg Gly Val Ser Phe Ala Glu Glu Asn 35 40 45 Glu Ser Leu Asp Asp Gln Asn Ile Ser Ile Ala Gly His Thr Phe Ile 50 55 60 Asp Arg Pro Asn Tyr Gln Phe Thr Asn Leu Lys Ala Ala Lys Lys Gly 65 70 75 80 Ser Met Val Tyr Phe Lys Val Gly Asn Glu Thr Arg Lys Tyr Lys Met 85 90 95 Thr Ser Ile Arg Asn Val Lys Pro Thr Ala Val Glu Val Leu Asp Glu 100 105 110 Gln Lys Gly Lys Asp Lys Gln Leu Thr Leu Ile Thr Cys Asp Asp Tyr 115 120 125 Asn Glu Glu Thr Gly Val Trp Glu Thr Arg Lys Ile Phe Val Ala Thr 130 135 140 Glu Val Lys 145 <210> 27 <211> 181 <212> PRT <213> Artificial Sequence <220> <223> Artificial Sequence <400> 27 Lys Pro His Ile Asp Asn Tyr Leu His Asp Lys Asp Lys Asp Glu Lys 1 5 10 15 Ile Glu Gln Tyr Asp Lys Asn Val Lys Glu Gln Ala Ser Lys Asp Lys 20 25 30 Lys Gln Gln Ala Lys Pro Gln Ile Pro Lys Asp Lys Ser Lys Val Ala 35 40 45 Gly Tyr Ile Glu Ile Pro Asp Ala Asp Ile Lys Glu Pro Val Tyr Pro 50 55 60 Gly Pro Ala Thr Arg Glu Gln Leu Asn Arg Gly Val Ser Phe Ala Glu 65 70 75 80 Glu Asn Glu Ser Leu Asp Asp Gln Asn Ile Ser Ile Ala Gly His Thr 85 90 95 Phe Ile Gly Arg Pro Asn Tyr Gln Phe Thr Asn Leu Lys Ala Ala Lys 100 105 110 Lys Gly Ser Met Val Tyr Phe Lys Val Gly Asn Glu Thr Arg Lys Tyr 115 120 125 Lys Met Thr Ser Ile Arg Asn Val Lys Pro Thr Ala Val Gly Val Leu 130 135 140 Asp Glu Gln Lys Gly Lys Asp Lys Gln Leu Thr Leu Ile Thr Cys Asp 145 150 155 160 Asp Leu Asn Arg Glu Thr Gly Val Trp Glu Thr Arg Lys Ile Phe Val 165 170 175 Ala Thr Glue Val Lys 180 <210> 28 <211> 3713 <212> DNA <213> A snowstorm <220> <223> A snowstorm <400> 28 caactttgta tagaaaagtt gctgtgcctt ctagttgcca gccatctgtt gtttgcccct cccccgtgcc ttccttgacc ctggaaggtg ccactcccac tgtcctttcc tataaaatg aggaaattgc atcgcattgt ctgagtaggt gtcattctat tctggggggt ggggtggggc 180 240. aggacagcaa gggggaggat tgggaagaca atagcaggca tgctggggat gcggtgggct ctatgggcgt tacataactt acggtaaatg gcccgcctgg ctgaccgccc aacgaccccc 300. 360. gcccattgac gtcaataatg acgtatgttc ccatagtac gccaataggg actttccatt gacgtcaatg ggtggagtat ttacggtaaa ctgcccactt ggcagtacat caagtgtatc 420 atatgccaag tccgccccct attgacgtca atgacggtaa atggcccgcc tggcattatg 480 540. cccagtacat gaccttacgg gactttccta cttggcagta catctacgta ttagtcatcg ctattaccat gcctcgaggg tacttatata agggggtggg ggcgcgttcg tcctcagtcg 600 cgatcgaaca ctcgagccga gcagacgtgc ctacggaccg tctagacaag tttgtacaaa 660 aaagcaggct gccaccatgc ccgccatgaa gatcgagtgc cgcatcaccg gcaccctgaa 720 cggcgtggag ttcgagctgg tgggcggcgg agagggcacc cccgagcagg gccgcatgac 780 caacaagatg aagagcacca aaggcgccct gaccttcagc ccctacctgc tgagccacgt 840 gatgggctac ggcttctacc acttcggcac ctaccccagc ggctacgaga accccttcct 900 gcacgccatc aacaacggcg gctacaccaa cacccgcatc gagaagtacg aggacggcgg 960 cgtgctgcac gtgagcttca gctaccgcta cgaggccggc cgcgtgatcg gcgacttcaa 1020 ggtggtgggc accggcttcc ccgaggacag cgtgatcttc accgacaaga tcatccgcag 1080 caacgccacc gtggagcacc tgcaccccat gggcgataac gtgctggtgg gcagcttcgc 1140 ccgcaccttc agcctgcgcg acggcggcta ctacagcttc gtggtggaca gccacatgca 1200 cttcaagagc gccatccacc ccagcatcct gcagaacggg ggccccatgt tcgccttccg 1260 1320 caagacccc atcgccttcg ccagatctcg agctcgatga cgcaccaagg aagccctcga 1380 ggacgcgtaa aggtaccaaa ggatcccgac ctaccgaccc agctttcttg tacaaagtgg 1440 tgatggccgg ccgcttcgag cagacatgat aagatacatt gatgagtttg gacaaaccac 1500 aactagaatg cagtgaaaaa aatgctttat ttgtgaaatt tgtgatgcta ttgctttatt 1560 tgtaaccatt ataagctgca ataaacaagt taacaacaac aattgcattc attttatgtt 1620 tcaggttcag ggggaggtgt gggaggtttt ttaaagcaag taaaacctct acaaatgtgg 1680 tagcggccgc ggcgctcttc cgcttctcg ctcactgact cgctgcgctc ggtcgttcgg 1740 ctgcggcgag cggtatcagc tcactcaaag gcggtaatac ggttatccac agaatcaggg 1800 gataacgcag gaaagaacat gtgagcaaaa ggccagcaaa aggccaggaa ccgtaaaaag 1860 gccgcgttgc tggcgttttt ccataggctc cgcccccctg acgagcatca caaaaatcga 1920 cgctcaagtc agaggtggcg aaacccgaca ggactataaa gataccaggc gtttccccct 1980 ggaagctccc tcgtgcgctc tcctgttccg accctgccgc ttaccggata cctgtccgcc 2040 tttctccctt cgggaagcgt ggcgctttct catagctcac gctgtaggta tctcagttcg 2100 gtgtaggtcg ttcgctccaa gctgggctgt gtgcacgaac cccccgttca gcccgaccgc 2160 tgcgccttat ccggtaacta tcgtcttgag tccaacccgg taagacacga cttatcgcca 2220 ctggcagcag ccactggtaa caggattagc agagcgaggt atgtaggcgg tgctacagag 2280 ttcttgaagt ggtggcctaa ctacggctac actagaagaa cagtatttgg tatctgcgct 2340 ctgctgaagc cagttacctt cggaaaaaga gttggtagct cttgatccgg caaacaaacc 2400 accgctggta gcggtggttt ttttgtttgc aagcagcaga ttacgcgcag aaaaaaagga 2460 tctcaagaag atcctttgat cttttctacg gggtctgacg ctcagtggaa cgaaaactca 2520 cgttaaggga ttttggtcat gagattatca aaaaggatct tcacctagat ccttttaaat 2580 taaaaatgaa gttttaaatc aatctaaagt atatatgagt aaacttggtc tgacagttac 2640 caatgcttaa tcagtgaggc acctatctca gcgatctgtc tatttcgttc atccatagtt 2700 gcctgactcc ccgtcgtgta gataactacg atacgggagg gcttaccac tggcccagt 2760 gctgcaatga taccgcgaga cccacgctca ccggctccag atttatcagc aaaaaccag 2820 ccagccggaa gggccgagcg cagaagtggt cctgcaactt tatccgccctc catccagtct 2880 attaattgtt gccgggaagc tagagtagt agttcgccag ttaatagttt gcgcaacgtt 2940 gttgccattg ctacaggcat cgtggtgtca cgctcgtcgt tggtatggc ttcattcagc 3000 tccggttccc aacgatcaag gcgagttaca tgatccccca tgttgtgcaa aaagcggtt 3060 agctccttcg gtcctccgat cgttgtcaga agtaagttgg ccgcagtgtt atcactcatg 3120 gttatggcag cactgcataa ttctcttact gtcatgccat ccgtaagatg cttttctgtg 3180 actggtgagt actcaaccaa gtcattctga gatagtgta tgcggcgacc gagttgctt 3240 tgcccggcgt caatacggga taataccgcg ccacatagca gaactttaaa agtgctcatc 3300 attggaaaac gttcttcggg gcgaaaactc tcaggatct taccgctgtt gagatccagt 3360 tcgatgtaac ccactcgtgc acccaactga tcttcagcat cttttactt caccagcgtt 3420 tctgggtgag caaaaacagg aaggcaaaat gccgcaaaaa agggaataag ggcgacacgg 3480 aaatgttgaa tactcatact cttccttttt caatattatt gaagcattta tcagggttat 3540 tgtctcatga gcggatacat atttgaatgt atttagaaaa ataaacaaat aggggttccg 3600 cgcacatttc cccgaaaagt gccacctgac gtctaagaaa ccattattat catgacatta 3660 acctataaaa ataggcgtat cacgaggccc tttcgtcggc gcgccgcggc cgc 3713 <210> 29 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 29 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactcthhc 60 atatcactah hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 30 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 30 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactcthhc 60 atcatcaath hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 31 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 31 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactcthht 60 atacaccath hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 32 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 32 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactctha 60 cattactach hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 33 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 33 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactcthht 60 caactacath hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 34 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 34 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactctha 60 acatatctch hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 35 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 35 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactcthht 60 accatacath hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 36 <211> 100 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 36 ggggcggggt ggggcgggga aatcatctca accactcaca tccactacca acactctha 60 ctcacttaah hhhhbaaaaa aaaaaaaaaa aaaaaaaaaa 100 <210> 37 <211> 80 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <220> <221> misc_feature <222> (39)..(48) <223> n is a, c, g, or t <220> <221> misc_feature <222> (80)..(80) <223> n is a, c, g, or t <400> 37 ctacacgacg ctcttccgat ctatggtgag caagggcgnn nnnnnnnntttttttttttt 60 tttttttttt tttttttttvn 80 <210> 38 <211> 54 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 38 aatgatacgg cgaccaccga gatctacact ctttccctac acgacgctct tccg 54 <210> 39 <211> 55 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 39 caagcagaag acggcatacg agatatatca gtgtgactgg agttcagacg tgtgc 55 <210> 40 <211> twenty four <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 40 ccactcacat ccactaccaa cact 24 <210> 41 <211> 27 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 41 gcagcgtcag atgtgtataa gagacag 27 <210> 42 <211> 61 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 42 aatgatacgg cgaccaccga gatctacact aatcttaaca ctctttccct acacgacgct 60 c 61 <210> 43 <211> 62 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 43 aatgatacgg cgaccaccga gatctacact cgtcggcagc gtcagatgtg tataagagac 60 ag 62 <210> 44 <211> 88 <212> DNA <213> Artificial sequence <220> <223> Artificial sequence <400> 44 caagcagaag acggcatacg agatctatcg ctgtgactgg agttcagacg tgtgctcttc 60 cgatcttcac atccactacc aacactct 88

Claims

1. A conjugate of a sortase with a nucleic acid or a derivative thereof.

2. The conjugate of claim 1, wherein the sortase is selected from the group consisting of sortase A, sortase B, and variants thereof.

3. The conjugate of any one of claims 1-2, wherein the sortase is mgSrtA.

4. Conjugates of cells and nucleic acids or their derivatives.

5. The conjugate of claim 4, wherein the nucleic acid or derivative thereof is conjugated to the plasma membrane of a cell.

6. The conjugate of any one of claims 4-5, wherein the cell is selected from the group consisting of a primary cell and an immortalized cell.

7. The conjugate of any one of claims 1 to 6, wherein the nucleic acid or derivative thereof is selected from the group consisting of DNA, RNA and PNA.

8. The conjugate of any one of claims 1 to 7, wherein the nucleic acid or derivative thereof is single-stranded.

9. A nucleic acid or derivative thereof comprising an anchor region, wherein the anchor region is guanine-rich.

10. A nucleic acid or a derivative thereof, comprising an anchor region, a region for PCR amplification, a barcode region for identification, and a capture sequence for sequence enrichment.

11. The nucleic acid or derivative thereof according to claim 10, wherein the anchor region is enriched in guanine, the region for PCR amplification is guanine-poor, and the capture sequence is a poly A sequence or a capture sequence suitable for high-throughput sequencing.

12. The conjugate according to any one of claims 1 to 8, wherein the nucleic acid or derivative thereof is the nucleic acid or derivative thereof according to any one of claims 9 to 11.

13. A method for preparing a conjugate of a cell and a nucleic acid or a derivative thereof, comprising contacting the nucleic acid or a derivative thereof, a cell and a sorting enzyme, wherein the nucleic acid or a derivative thereof is conjugated to the cell, and wherein the conjugation of the nucleic acid or a derivative thereof to the cell is catalyzed by the sorting enzyme.

14. The method of claim 13, wherein the cells are selected from the group consisting of primary cells and immortalized cells.

15. The method of any one of claims 13-14, wherein the nucleic acid or derivative thereof is conjugated to the plasma membrane of a cell.

16. The method of any one of claims 13-15, wherein glycosaminoglycans associated with cell membranes participate in the conjugation.

17. The method of claim 16, wherein the glycosaminoglycan is selected from the group consisting of heparin, heparan sulfate, chondroitin sulfate, and dermatan sulfate.

18. The method of any one of claims 13-17, wherein the sortase is selected from the group consisting of sortase A, sortase B, and variants thereof.

19. The method of any one of claims 13-18, wherein the sortase is mgSrtA.

20. The method of any one of claims 13 to 19, wherein the nucleic acid or derivative thereof is selected from the group consisting of DNA, RNA and PNA.

21. The method of any one of claims 13 to 20, wherein the nucleic acid or derivative thereof is single-stranded.

22. The method of any one of claims 13 to 21, wherein the nucleic acid or derivative thereof is a nucleic acid or derivative thereof according to any one of claims 9 to 11.

23. The method of any one of claims 13-22, wherein the conjugation occurs in vitro or in vivo.

24. The method of any one of claims 13 to 23, wherein the cell is first contacted with the nucleic acid or derivative thereof and then contacted with the sortase.

25. The method of any one of claims 13-23, wherein the cell is first contacted with the sortase and then with the nucleic acid or derivative thereof.

26. The method of any one of claims 13-25, wherein the conjugation occurs in vitro in a reaction medium, and wherein the nucleic acid or derivative thereof is present in the reaction medium at a concentration ranging from about 1 nM to about 10 μM.

27. The method of claim 26, wherein the contacting is performed at about 4°C to about 40°C.

28. The method of any one of claims 26 to 27, wherein the contacting is performed for about 1 minute to 30 minutes.

29. The method of any one of claims 26-28, further comprising terminating the conjugation of the nucleic acid or derivative thereof to the cell after the contacting occurs for about 1 minute to 30 minutes.

30. A method for delivering a nucleic acid or a derivative thereof to a cell, comprising providing a nucleic acid or a derivative thereof and a sortase to the vicinity of a cell, wherein the nucleic acid or a derivative thereof is conjugated to the cell by catalysis of the sortase, and wherein the nucleic acid or a derivative thereof is subsequently internalized into the cell.

31. The method of claim 30, wherein the method is performed in vivo or in vitro.

32. The method of any one of claims 30-31, wherein the nucleic acid or derivative thereof comprises a drug.

33. The method of any one of claims 31-32, wherein the nucleic acid or derivative thereof comprises a vaccine.

34. The method of any one of claims 30-33, wherein the sortase is selected from the group consisting of sortase A, sortase B, and variants thereof.

35. The method of any one of claims 30-34, wherein the sortase is mgSrtA.

36. A method for barcoding a cell, comprising: contacting a nucleic acid or a derivative thereof, a cell, and a sortase, wherein the nucleic acid or a derivative thereof is conjugated to the cell, wherein the conjugation of the nucleic acid or a derivative thereof to the cell is catalyzed by the sortase, and wherein the nucleic acid or a derivative thereof comprises the nucleic acid or a derivative thereof of any one of claims 9 to 11; and The cell is identified by determining the identity of the nucleic acid or derivative conjugated to the cell.

37. The method of claim 36, wherein the method is performed in vivo or in vitro.

38. The method of any one of claims 36-37, wherein the cell is selected from the group consisting of a primary cell and an immortalized cell.

39. The method of any one of claims 36-38, wherein the sortase is selected from the group consisting of sortase A, sortase B, and variants thereof.

40. The method of any one of claims 36-39, wherein the sortase is mgSrtA.

41. The method of any one of claims 36-40, wherein the identity of the nucleic acid or derivative conjugated to the cell is determined by high throughput sequencing.

42. A kit comprising a sortase and a nucleic acid or a derivative thereof.

43. The kit of claim 42, wherein the nucleic acid or derivative thereof is a nucleic acid or derivative thereof according to any one of claims 9 to 11.